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ABSTRACT 
 
The broad goals of this dissertation were to explore possible causes of erectile 
dysfunction (ED), and examine outcomes associated with the condition. To address these 
objectives, data from the Vietnam Era Twin Study of Aging (VETSA), a longitudinal 
study of cognitive aging, were utilized.  
Previous research demonstrated moderate heritability of ED in middle-aged men, 
but questions remain about the replicability of these findings given that only one study 
exists on the topic and it utilized an unvalidated ED measure. Additionally, it is unknown 
to what extent genetic factors account for stability and change of ED symptomatology 
over time. In the first study, we conducted a longitudinal assessment of ED using the 
Sexual Health Inventory for Men (SHIM) administered to 715 male twins. Results 
revealed that the heritability (proportion of variance explained by genetic factors) of ED 
is 53% at age 55 and 33% by age 60. 
Over the past two decades ED has been recognized as primarily a disorder of 
vascular dysfunction. Inflammation is an important correlate of vascular dysfunction. 
Chapter 2 examined the association of ED with four inflammatory serum protein indices 
	 viii 
[albumin, globulin, albumin/globulin ratio (AGR), and the albumin*globulin interaction 
(AGI)] in 388 men free from cardiovascular disease (CVD). Results indicated that the 
AGR, albumin, and globulin protein levels are significantly associated with ED, even 
after accounting for other risk factors. Intriguingly, AGR and globulin levels were found 
to be more strongly associated with ED than conventional vascular risk factors, such as 
hypertension, high cholesterol, obesity, and smoking.  
Given the negative impact that vascular disease has on cognition, Chapter 3 
explored whether men with ED are at greater risk for experiencing cognitive decline 
compared to healthy peers. In total, 485 men free from CVD were administered cognitive 
tests across 13 domains. Tests were readministered 5 years later. Results revealed that 
men with ED were more likely to show significant decline on tasks of set-shifting, 
tool/mechanical knowledge, vocabulary, and verbal fluency.  
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GENERAL INTRODUCTION 
 
“When the member is no way stirred and can never perform the action of coition, this is a sign of 
frigidity of nature, but when it is stirred and yet cannot become erect, it is a sign of witchcraft.” 
Malleus Malleficarum, 1486 
 
Over the past few centuries, our conceptualization of erectile dysfunction (ED) has 
dramatically evolved. The quotation above (taken from Morley, 1986) comes from the Malleus 
Maleficarum, written in 1486, as a treatise on the prosecution of witchcraft (Kramer, 1486). 
During this era, it was believed that male impotence arose from curses cast by witches. While this 
perception of ED may be discounted as a byproduct from a particularly dark time during the 
Spanish Inquisition, over a century later our understanding of ED had changed, but it had 
certainly not improved. In France during the 16th and 17th centuries, impotence was considered 
to be criminal behavior, and served as legal grounds for a divorce (Roach, 2009). Though this 
practice was declared obscene in 1677, the stigma and misunderstanding surrounding the 
condition survived well into the 20th century. In Sigmund Freud’s pivotal work “The Most 
Prevalent Form of Degradation in Erotic Life” (1912) he discussed how impotence was due to the 
Oedipal complex - an unresolved fixation on one’s mother. 
By the 1920s and 1930s, Dr. John Brinkley garnered substantial attention on his radio 
programs as he discussed what today might seem as outlandish cures for erectile dysfunction 
(Hutchens, 1942). His recommendations ranged from expensive goat gland implants and 
"mercurochrome" injections, to operations by Serge Voronoff, a French surgeon who became 
famous for grafting monkey testicle tissue on the testicles of men to improve virility (Gillyboeuf, 
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2000). 
Steckel, one of Freud’s students, declared (albeit incorrectly) that 90% of impotence was 
psychogenic in nature (Steckel & Boltz, 1927). This belief carried through the 1960s and 1970s, 
and persisted until the early 1980s, when Virag (1982) discovered that penile injection of 
papaverine, a non-specific vasoactive agent, could artificially produce an erection. This effect 
was replicated in 1983, when Virag’s colleague British physiologist Giles Brindley, Ph.D. 
dropped his pants in front of a bewildered audience at the American Urologics Association 
conference in Las Vegas to provide personal proof that injection of papaverine could induce an 
erection (Klotz, 2005). With this act, Brindley made sure that the papaverine discovery was not 
overshadowed at the conference. (An attending urologist later penned a first-hand account of the 
experience: How (Not) to Communicate New Scientific Information: A Memoir of the Famous 
Brindley Lecture [Klotz, 2005]). It was known that papaverine was an alpha-blocking vasodilator, 
and the mechanism of action was understood to be corporal smooth muscle relaxation. From this, 
researchers began conceptualizing impotence as a vascular disorder. It was this original revelation 
by Virag and Brindley that established and propelled the development of modern vasodilatory 
medications (e.g. Viagra) that are used to treat the symptoms of ED.  
Following the papaverine discovery, it became possible to investigate the physiological 
mechanisms of the vasculature in men with and without ED, improving our understanding of how 
erections function (and dysfunction). Almost overnight, male sexuality moved away from the 
psychoanalytic sphere of Freud, and became a highly medicalized topic. In contrast to the original 
reports by Steckel, we now know that there is an organic cause underlying the disorder in over 
80% of men with the condition (Jackson, Rosen, Kloner, & Kostis, 2006; Kendirci, Nowfar, & 
Hellstrom, 2005; Solomon, Man, & Jackson, 2003). In the past two decades, ED has been lauded 
as an early indicator of microvascular disease (Feldman, Goldstein, Hatzichristou, Krane, & 
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McKinlay, 1994).  
Not only is ED frequently due to vasculopathic processes, it has been well established 
that ED is a strong predictor of future cardiovascular diagnoses. For example, ED frequently 
precedes the onset of angina by 2-3 years and adverse cardiovascular events by 3-5 years 
(Hodges, Kirby, Solanki, O'Donnell, & Brodie, 2007 O'Donnell, & Brodie, 2007). Over the 
course of 10 years, men with moderate-to-severe ED are at a 65% increased relative risk of 
developing coronary heart disease and a 43% increased risk of stroke compared to those without 
ED (Ponholzer, Temml, Obermayr, Wehrberger, & Madersbacher, 2005).  
Cardiovascular diseases continue to be the leading cause of morbidity and mortality in 
the world (WHO, 2010). However, in recent years, the incidence of cardiovascular diseases have 
tapered off (Luepker, 2008), believed largely to be due to risk factor reduction and improved 
treatment of subclinical cardiovascular syndromes and their risk factors. In this sense, ED is a 
highly important condition to study as it is powerfully predictive of future cardiac events and may 
aid in early detection of cardiovascular damage. Miner and colleagues (2009) discuss the 
possibility that ED presents a “window of curability” for cardiac diseases, in which progression 
of vascular dysfunction might be attenuated or reversed by medical intervention if caught early 
enough. Understanding the causes, consequences, and correlates of ED is important to elucidate 
its utility in predicting incident cardiovascular disease. 
From an etiological perspective, understanding the genetics of ED is useful, as we know 
that many cardiovascular diseases have demonstrated significant heritability. The Framingham 
Heart Study found that genes accounted for approximately 38% of the variance in atherosclerosis 
(Fox et al., 2003). Similar estimates have been found with regard to angina (Zdravkovic, Wienke, 
Pedersen, & de Faire, 2007a), myocardial infarction (Zdravkovic, Wienke, Pedersen, & de Faire, 
2007b), and stroke (Bevan, 2012). Death from coronary heart disease (CHD) was found to be 
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moderately heritable, with genes accounting for 57% of the variance (Zdravkovic et al., 2002). 
These estimates may not be surprising given that Elder et al. (2009) found similar levels of 
genetic influence across cardiovascular risk factors. Specifically, they found that plasma 
cholesterol and triglyceride concentrations were highly heritable (57-77%), while waist 
circumference, plasma glucose, insulin, insulin resistance, and blood pressure were moderately 
heritable (43-56%).  In this sense, understanding the genetic underpinnings of ED may provide 
insight into genetic contributions to vascular dysfunction and subclinical vascular disease 
development. The first chapter of this dissertation has been devoted to addressing this research 
topic. 
The second chapter discusses another possible contributor to the development of ED: 
inflammation. Over the last dozen years, appreciation of the role of inflammation in CVD has 
burgeoned (Libby, 2006). It is now known that inflammation is involved in every stage of 
atherosclerosis. Although it is not proven that that the relationship between inflammation and 
cardiovascular disease is causal, inflammation is routinely present in patients with cardiac illness, 
and it is believed that inflammation is responsible for the build-up of plaque on the walls of the 
arteries (Hansson, 2005). In fact, atherosclerosis is largely prevented when the genes critical for 
the initiation or maintenance of inflammation are knocked-out in mice (Brånén et al., 2004). 
Consistent with the idea that ED represents subclinical vascular disease, several studies 
have demonstrated that inflammation is also present in ED (Giugliano et al., 2004; Vlachopoulos, 
Rokkas, Ioakeimidis, & Stefanadis, 2007). Studies investigating inflammatory biomarkers in 
relation to ED are almost exclusively limited to CRP and pro-inflammatory cytokines 
(Vlachopoulos, Rokkas, Ioakeimidis, & Stefanadis, 2007 & Stefanadis, 2007), as these are best 
characterized inflammatory indices. However, other routinely collected hematological parameters 
of inflammation do exist. Two such parameters are albumin and globulin. Albumin and globulin, 
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which are the two major constituents of serum proteins, have recently garnered attention as 
pivotal players in the inflammatory cascade. They have been linked with increased risk for 
cardiovascular morbidity (Schalk, Visser, Deeg, & Bouter, 2004) and mortality (Fischer et al., 
2014; Godsland, North, & Johnston, 2011)  
Despite the accumulating data suggesting that altered albumin and/or globulin levels may 
be implicated in the inflammatory process, the biological mechanism linking these variables to 
increased cardiovascular morbidity and mortality remains unknown. Much of the research on 
these markers occurs in the context of extant CVD (as opposed to studies on CVD prediction), 
and less is known about when and how these proteins contribute to the progression toward CVD 
development. The literature is also mixed regarding whether it is albumin or globulin (or both) 
that is more important in CVD. Looking at the relationships between these variables and erectile 
difficulties allows us to determine if abnormal albumin and/or globulin levels are at work prior to 
CVD, or if they are simply a byproduct of the established disease. Further, better understanding 
of the inflammatory cascades implicated in impotence may aid in our conceptualization of ED 
development, and could thereby shed light on anti-inflammatory treatments for the disorder. 
Chapter two of the dissertation looks at the associations among ED, albumin, and globulin, in the 
context of more traditional cardiovascular risk factors.  
 In contrast to the first two chapters, which discuss pathways to the development of ED, 
the final chapter of the dissertation discusses outcomes associated with impotence. Specifically, 
we are interested in learning about how ED may be associated with cognitive functioning. Given 
that there is a large body of literature centered on cognitive impairment in the context of vascular 
disease, our analyses are looking at whether ED – a harbinger of vascular disease – is already 
associated with diminished cognitive performance. Vascular disease contributes to the majority of 
dementia cases, either directly as in vascular dementia (Román, Erkinjuntti, Wallin, Pantoni, & 
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Chui, 2002), or indirectly by propelling Alzheimer’s disease pathology (Polidori, Pientka, & 
Mecocci, 2012). Catching vascular disease early is important to slow or attenuate its negative 
effects on brain health. 
Intriguingly, ED has typically been neglected in neuropsychological studies on aging. 
Our lab reported the first findings associating ED with neuropsychological performance (Moore 
et al., 2014). This cross-sectional study found that men with ED performed significantly worse 
than their healthy peers on nearly all of the cognitive domains assessed in a comprehensive 
battery of cognitive tests. Findings were most striking in the attention-executive-psychomotor 
speed domains, which is consistent with cognitive profile typically found in cardiovascular 
disease patients. These domains are subserved by the frontosubcortical networks, which are 
particularly vulnerable to ischemic damage. Because penile arteries are similar in size than 
cerebrovascular arteries, the possibility remains that ED may signal accruing cerebrovascular 
damage. Though our first paper on this topic laid the groundwork for future research, the cross-
sectional nature of the study precluded an unequivocal determination of causality. By following 
this sample over time, we can better characterize the temporal nature of the relationship between 
ED and cognition. The final chapter of this dissertation explores how ED is associated with 
cognitive change across time. 
In summary, though ED has had a long and stigmatizing past, it is now recognized as a 
critically important health condition. Sharpening our understanding of ED has widespread 
implications. Not only is ED associated with diminished quality of life (FuglMeyer, Lodnert, 
Branholm, & FuglMeyer, 1997), but ED is a precursor to cardiovascular disease – a prominent 
cause of dementia and the leading cause of death in the world (WHO, 2010). On top of this, 
cardiovascular disease is the most costly medical condition in the United States economy (Druss, 
Marcus, Olfson, & Pincus, 2002), as it causes more hospital spending, more lost work days, and 
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more activity impairments than any other morbidity. Thus, research on ED is warranted because it 
may trim healthcare costs by preventing or delaying overt cardiovascular diseases and vascular 
induced cognitive impairment. And, at a more basic level, ED is a troubling condition in its own 
right, and better management of the condition may result in decreased stigma and enhanced 
quality of life for men across the world. Though the following three chapters will fill in some of 
the current holes in the ED literature, research on the modern conceptualization of the condition is 
still in its nascence.  	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CHAPTER I: A Twin Study on Erectile Dysfunction: 
Estimates of Heritability and Genetic Correlation Over 
Time 	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INTRODUCTION 
Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain an 
erection sufficient for satisfactory sexual performance (National Institutes of Health Consensus 
Development Panel on Impotence, 1992). Over the past two decades ED has been linked to 
several cardiovascular diseases and risk factors, including hypertension (Burchardt et al., 2000), 
high cholesterol (Wei et al., 1994), diabetes (Grover et al., 2006), obesity (Riedner et al., 2006), 
physical inactivity (Derby et al., 2000), and cigarette smoking (Kupelian et al., 2007). Inverse 
relationships of ED with age (Bacon et al., 2003) and education (Johannes et al., 2000) have also 
been revealed.  
Given that many of these risk factors have shown at least moderate heritability, a genetic 
component of ED has also been explored. Fischer et al. (2004) utilized a classic twin design to 
determine the heritability of this condition and explore whether an ED-specific genetic influence 
existed or if the genetic influence was accounted for by ED risk factors. In their study, 890 
monozygotic and 619 dizygotic twin pairs completed a questionnaire that was restricted to two 
items about the difficulty in the past month of (1) having an erection and (2) maintaining an 
erection. Respondents rated their ED on a 6-point Likert scale ranging from ‘very good’ to ‘no 
erection’. These scores were then used to create binary classifications for each question. After 
controlling for diabetes, hypertension, coronary heart disease, body shape, cigarette smoking, and 
alcohol use, the heritability estimates for difficulty having and maintaining an erection were 29% 
and 35%, respectively. 
The findings by Fischer and colleagues (2004) were intriguing and, a decade later, still 
serve as the only twin study on ED. However, the study was plagued with two important 
limitations that may have impacted its results. First, the study did not utilize a validated ED 
assessment measure, but rather relied on responses from only two questions to determine ED 
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status. While the questions they asked are highly relevant to the diagnosis of ED, erectile 
functioning is a multidimensional morbidity that warrants a more comprehensive assessment. For 
example, intercourse satisfaction is a central element in the NIH definition of ED. By relying on 
two questions to establish an ED diagnosis, important diagnostic information is omitted.   
 Second, although the subjects’ average age was 50 years in the study by Fischer et al., the 
heritability estimate is based on a wide range of ages (42 – 60). Because ED prevalence is tightly 
linked with advancing age (Bacon et al., 2003), utilizing such a wide window may affect the 
heritability estimate of ED. Relatedly, the mean age of the sample in Fischer’s study was 
approximately 50 years, which is relatively young with respect to the prevalence pattern for ED. 
For example, Johannes et al. (2000) found that the risk of erectile dysfunction was almost 4 times 
higher for men 60 to 69 than for those 40 to 49 years old. It is plausible that assessing the genetic 
influences on ED in a more at-risk age range would reveal different patterns of heritability.   
The overarching goal of the proposed study was to replicate and extend the findings by 
Fischer et al. (2004) by (1) utilizing a validated and more comprehensive assessment of ED, (2) 
assessing ED in an older sample with a more constricted age range, and (3) examine ED 
heritability and prevalence five years apart, which will allow us to assess the genetic correlation 
of the manifestation of ED at different time points. Assessing ED longitudinally is highly 
important as research has shown that a substantial number of men will have their erectile 
dysfunction remit or progress over time (Travison et al., 2007). 
 
METHODS 
Participants 
Study participants were men who participated in the Vietnam Era Twin Study of Aging 
(VETSA; Lyons et al., 2009). VETSA participants were assessed at one of the two testing sites 
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(Boston University and the University of California, San Diego) or, in rare circumstances, elected 
to have a research assistant travel to them. The first wave of the VETSA study (VETSA 1) 
occurred between 2003-2007, while the second wave (VETSA 2) occurred from 2009-2013. The 
VETSA study is a comprehensive study primarily focused on cognitive aging. Though the focus 
of VETSA is not on ED, a wide range of demographic and health information (including ED 
symptoms) is collected from the participants as part of our comprehensive work-up. Informed 
consent was obtained after the nature and possible consequences of the studies were explained. 
The study was approved by the Boston University and University of California, San Diego, 
Institutional Review Boards. Zygosity for VETR members was initially determined by a 
combination of questionnaire and blood-group type. Eisen, Neuman, Goldberg, Rice, and True 
(1989) reported that zygosity determined utilizing this protocol was 95% accurate. VETSA 
participants underwent additional zygosity testing via analysis of 25 microsatellite markers.  
As discussed in greater detail below, the ED assessment evolved over the course of the 
study. Though the full Sexual Health Inventory for Men (SHIM) was given at VETSA 1, only 
select questions from the measure were administered at the beginning of VETSA 2. Over time, 
more questions were re-introduced and eventually the full ED measure was included. As such, not 
all participants received the full ED assessment and accordingly were excluded from the present 
analyses. The final sample consisted of 715 men with an average age of 55.5 (SD=2.5; range=51-
60) at Time 1 and an average age of 61.2 (SD=2.5; range=56-66) at Time 2. 
 
Erectile Dysfunction Assessment 
Erectile function was assessed by the five questions that comprise the International Index 
of Erectile Function-5 (IIEF-5) (also referred to as the Sexual Health Inventory for Men [SHIM]) 
(Rosen et al., 1999), a well-validated self-report questionnaire. The IIEF-5 is a shortened version 
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of the IIEF-15 (Rosen et al., 1997), which is a 15-item questionnaire that generates four domain 
scores: erectile function, orgasmic function, sexual desire, and intercourse satisfaction. The IIEF-
5 (SHIM) was created after the IIEF-15, in response to clinicians and researchers seeking a 
shorter erectile dysfunction screening measure.  All five items on the SHIM come from the IIEF-
15 (four come from the erectile function domain of the IIEF-15 and one comes from the 
intercourse satisfaction domain of the IIEF-15). Accordingly, SHIM scores can be calculated 
from IIEF-15. In our study, we used the IIEF-15 at VETSA 1 and the SHIM at VETSA 2. For the 
present analyses, we relied exclusively on SHIM scores calculated at both time points to allow 
direct comparison from VETSA 1 to VETSA 2.  
Responses to each of the five items on the SHIM are based on a rating scale from 0 to 5 
or from 1 to 5 (depending on the item). They are summed to arrive at a total score that can range 
from 1 to 25, with higher scores indicating better sexual health. ED is classified as mild (17-21), 
mild to moderate (12-16), moderate (8-11), and complete ED (1-7). Scores ranging from 22-25 
suggest no clinically significant erectile difficulties. A binary classification of ED is defined as 
the presence of ED (scores ranging from 1-21) or absence of ED (scoring ranging from 22-25). 
Because the ED variable is not normally distributed, the binary classification of ED will be the 
variable of interest. 
 
Covariate Assessment 
As cardiovascular risk factors are frequently comorbid with ED, we provide descriptive 
statistics and prevalence estimates of cardiovascular diseases, diabetes, hypertension, high 
cholesterol, body mass index (BMI), cigarette smoking (total pack years), and depression for the 
sample analyzed. Cardiovascular disease was defined as angina, peripheral vascular disease, 
myocardial infarction, heart failure, stent placement or heart surgery. With the exception of BMI, 
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depression, cigarette smoking, high cholesterol, and hypertension, history of any of these risk 
factors was based on participants’ endorsement when asked if they had ever been told by a doctor 
that they had the condition. BMI was defined as the individual's body mass divided by the square 
of their height, given in units of kg/m2. Depressive symptoms were measured by the Center for 
Epidemiologic Studies-Depression Scale (CES-D). Hypertension was ascribed to participants if 
they endorsed that a physician had given them this diagnosis, or had blood pressure on the day of 
testing above 140 systolic or 90 diastolic. Assessment of high cholesterol changed from VETSA 
1 to VETSA 2. At VETSA 1, high cholesterol was ascribed if participants were taking 
cholesterol-lowering medication. At VETSA 2, blood assays had been included in the testing 
protocol, allowing us to examine cholesterol levels directly. At VETSA 2, high cholesterol was 
ascribed to participants who or endorsed that a physician had diagnosed them as having 
hypercholesterolemia, were taking cholesterol lowering medication, or if their blood draw on the 
day of testing had LDL, HDL, and/or total cholesterol levels conventionally considered to be high 
risk (LDL: > 160 mg/dL; HDL: <40 mg/dL; Total cholesterol: >240 mg/dL). 
Lifetime smoking at VETSA 1 was indexed by pack years (cigarettes smoked per day x 
years the participant smoked/20). Participants were not queried about their current smoking 
frequency at VETSA 2, but an estimated pack years variable was created. To do this, we first 
calculated how many pack years they had at VETSA 1. If they had were no longer smoking at 
VETSA 1, we assumed that their pack years had not increased from VETSA 1 to VETSA 2 (i.e. 
VETSA 1 pack years = VETSA 2 pack years). If they were currently smoking at VETSA 1, we 
assumed that they would likely still be smoking five years later, and thus their VETSA 2 pack 
years was adjusted to reflect an additional 5 years of smoking. In other words, if a man had 30 
pack years (e.g., 15 years of smoking 2 packs per day) at VETSA 1 and endorsed being a current 
smoker, his new estimated pack years value at VETSA 2 would be 40 (30 pack years / 15 years of 
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smoking = a rate of 2 pack years/ year; 2 pack years/ year * 5 additional years=10; 30 packyears 
at VETSA 2 + an additional 10 pack years by VETSA 2 = 40 pack years). Participants who 
endorsed never smoking in their lifetime were given a pack years of zero.  
 
Statistical Analysis 
First, repeated measures ANOVAs were used to determine if prevalence rates of 
cardiovascular risk factors changed from VETSA 1 to VETSA 2.  Next, biometrical modeling 
was used to measure the genetic and environmental influences of ED. We assume that variation in 
ED is due to a combination of additive genetic (A), shared environmental (C), and nonshared 
environmental (E) factors. The additive genetic component of variance (i.e., heritability) 
represents the polygenic influence. The common environmental variance includes all 
environmental influences that are shared by members of a twin pair (e.g. childhood home life), 
thereby making the twins more similar to one another. In contrast, the unique environment 
represents environmental factors that members of a twin pair do not share (e.g. SES as an adult), 
thereby making them different from one another. Measurement error is also included in the 
unique environmental variance. Our analyses utilized the simplest and most frequently applied 
multivariate model, the correlated factors model. In the correlated factors model, in addition to 
the A, C, and E parameters derived for each trait, correlations between latent variables, rA, rC, 
and rE can also be assessed. These symbols represent the genetic correlation, the shared 
environmental correlation, and the nonshared environmental correlation, respectively. 
 
RESULTS 
The mean age of participants at the baseline SHIM administration in VETSA 1 was 55.5 
(SD=2.5; range=51-60) years. Mean age for re-administration during VETSA 2 was 61.2 
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(SD=2.5; range=56-66) years. The phenotypic correlation of SHIM at age 55 with SHIM at age 
60 was .54 (p=<.001). Mean SHIM score at VETSA 1 was 17.3 (SD=8.8), with 48.0% of 
participants being classified as having ED. At VETSA 2, the mean SHIM score was 14.6 
(SD=8.8) (lower scores indicating increased erectile difficulties), with 65.3% of participants 
being classified as having ED.  Change could only be computed for the 715 subjects who 
participated at both VETSA time points. Descriptive statistics on these participants and their 
cardiovascular risk factors at VETSA 1 and VETSA 2 can be found in Table 1.1. With the 
exception of depression, all cardiovascular risk factors appeared to increase in prevalence from 
VETSA 1 to VETSA 2. 
We obtained maximum-likelihood estimates of the contributions of additive genetic 
effects (A), environmental effects shared by twins (C), and nonshared (individual-specific) 
environmental effects unique to individual twins (E) by using the structural equation modeling 
program Mx (Neale, Boker, Xie, & Maes, 2003). Several models were fitted to the data, and 
likelihood-ratio tests were conducted for differences between means and covariance structures 
(see Table 1.2). Model 1 allowed each variance, covariance, and mean to take its own value in 
MZ and DZ twins. Subsequently, reduced models with fewer parameters were tested to determine 
whether they fit the data as well as the full model (Model 1). We compared Models 2 through 13, 
presented in Table 1.2, to the full model (Model 1). These tests indicated that there is a significant 
difference in covariances for MZ versus DZ pairs, as would be expected if there were genetic 
effects. We see that the best fitting model is Model 12, in which the shared environmental factors 
at age 55 and at age 60, along with the correlation in shared environment, are fixed at zero (in 
other words they were dropped from the model), and the genetic correlation is fixed at 1.0. 
Effects of A, C, and E at baseline and at follow-up derived from the full bivariate model 
are presented in Figure 1.1 as both path coefficients and proportions of variance; correlations 
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between the latent factors (e.g., shared environmental influences) are also presented.  Results 
revealed that at age 55, 53% of the variance in ED is due to genetics. By age 60, the heritability 
drops to 33%. In contrast, the influence of the unique environment appears to increase over time, 
with unique environment accounting for 47% of the variance in ED at age 55, and 67% of the 
variance by age 60.  There was no significant influence of the common environment, as this was 
dropped from the analyses. The correlation between genetic influences at age 55 and age 60 was 
1.0 in the best-fitted model, indicating that the genes that influence ED at age 55 and at age 60 are 
identical. The correlation between unique environmental effects was .44, suggesting that 44% of 
the unique environmental factors that influenced ED at V1 and V2 overlap.  
 
DISCUSSION 
Our results indicate that genes do influence the etiology of ED. Further, while the same 
genes appear to be acting from age 55 to age 60, the overall variance explained by genes appears 
to decrease over time, declining from 53% to 33%. In contrast to this, unique environmental 
factors appear to account for more variance in ED as we age. The common environment did not 
explain significant variance at either time point. 
Overall, our results are generally consistent with the findings by Fischer and colleagues 
(2004), which found moderate heritability (34%) for dysfunction in ability to have an erection, 
and moderate heritability (39%) for ability to maintain an erection. When contrasted with their 
findings, we demonstrated a somewhat higher heritability estimate for ED at age 55 (53%), 
though this still fell broadly within the moderate range. Our studies boast several important 
differences. First, the ED measure used in our study differed from that by Fischer. While the 
SHIM contains two questions similar to those used by Fischer (e.g. [1] difficulty getting an 
erection and [2] difficulty maintaining an erection), it also includes three other items that assess 
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intercourse satisfaction, frequency of getting an erection, and frequency of maintaining an 
erection. Further, while the previous study analyzed the heritability of response to each item, we 
analyzed the total score from the 5-question SHIM. While single-item assessment may have 
provided more nuanced information, we believe utilizing a validated measure (when possible) is 
an important contribution to the literature. Lastly, Fischer’s study utilized a sample with a wide 
range of ages (42 – 60), in contrast to our more age-constricted sample. Because ED prevalence is 
tightly linked with advancing age, utilizing such a wide window may affect the heritability 
estimate of ED. Our data suggests that advancing age is associated with a notable decrease in 
heritability, and collapsing data from across a wide age-range may be problematic because age-
specific heritability trends may be washed away. 
The decline in ED heritability over time is consistent with other studies that have looked 
at decreasing patterns of genetic influence on cardiovascular disease as we age (Zdravkovic et al., 
2002). It may be that, regardless of genetics, our vascular system is more vulnerable to insults 
with each added decade. As cardiovascular risk factors become increasingly more prevalent as we 
get older, this may reduce the importance of genetic variation. 
Potential limitations of the study bear discussion, as they may have affected the 
interpretability and generalizability of our findings. First, rather than using a direct physiological 
assessment to classify ED, we relied on responses from a self-report questionnaire. However, 
self-reported ED has shown to be valid, and is actually considered the most appropriate method 
for assessing this condition (Rosen et al., 2002). Further, we utilized the SHIM, which is a well-
validated measure that is considered the ‘gold standard’ self-report assessment in the field 
(Cappelleri & Rosen, 2005; Rosen, Cappelleri, Smith, Lipsky, & Peña, 1999). 
 Despite the strong psychometrics of the SHIM, it also has limitations that affect the 
manner in which it is used and interpreted. The normative group used in validating this measure 
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(and its scoring classification system) was composed exclusively of samples from the United 
States and the United Kingdom. Though the optimal cutoff score to determine ED in these 
samples was found to be 21, it may differ in other samples. For example, Lim et al. (2003) 
conducted a cross-cultural adaptation and validation study on the use of the SHIM in Malaysia 
and found the best cutoff score in their sample to be 17. Thus, although the original classification 
structure was appropriate for the present study, future research is warranted on the utility and 
generalizability of the SHIM in other cultures. 
Relatedly, prevalence rates and etiologies of ED may differ across cultures. Because risk 
factors for ED vary across countries (e.g. prevalence of cardiovascular diseases, somatic 
manifestations of psychopathology), it is plausible that genetic influences may serve a greater or 
lesser role in other regions than it does in the United States.  Given these factors, it is important to 
note that the findings in the present study may not be reflective of men in other parts of the world. 
Despite this limitation, we utilized a nationally representative sample that is similar to its age-
cohort of American men in terms of socioeconomic status and health characteristics (Kremen et 
al., 2012). Though all of our participants served in the U.S. military sometime between 1965 and 
1975, most did not serve in combat. Detailed descriptions of the VETR and ascertainment 
methods have been previously reported (Kremen, Franz, & Lyons, 2012; Kremen et al., 2006).  
Another limitation within our study is that our ED measure changed between the two 
waves of the study (VETSA 1 and VETSA 2). Because not all participants received the full 
SHIM questionnaire, we excluded approximately half of our sample due to missing data. 
However, it is unlikely that this exclusion bias is producing the significant heritable effects—to 
do so would mean that the likelihood of excluding ED-concordant MZ pairs relative to all MZ 
pairs was different than the likelihood of excluding ED-concordant DZ pairs relative to all DZ 
pairs. 
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The mechanisms underlying ED-specific genes remain unknown. However, gaining a 
better understanding of the genetics of ED may shed light on pathways to cure the condition, 
and/or improve the current pharmaceutical agents. While the extant ED medications improve 
erection in some men, they simply address the symptoms and do not cure the underlying 
pathology. Utilizing genetic markers in the diagnosis and treatment of ED may yield better 
efficacy for ED medications and may aid in early identification of those at risk for developing the 
condition. 
 In 2005, Melman and colleagues began the first (and, at present, only) human trial of 
gene therapy to attempt to increase the expression of ion channels in penile smooth muscle by 
administering different doses of hMaxi-K, a "naked" DNA plasmid that acts on the smooth 
muscle. The trial was small (n=11) but found that the 5 participants given the two highest doses 
of hMaxi-K had sustained improvements in erectile function through the end of the study six 
months later. Whereas traditional pharmacological medications work by temporarily relaxing the 
smooth muscles and increasing blood flow, genetic therapies attempt to cure ED by modifying 
genetic material, rather than improving symptoms.  
Although the findings by Melman and colleagues represent an exciting application of the 
field of molecular genetics, it is to date the only FDA-approved open clinical trial treating ED 
with gene transfer. Currently, much of the research on ED genetics is still exploratory in nature 
and relies heavily on animal models. The translation of findings from animal studies to gene 
therapy in humans has been a slow process, in part because there are serious safety concerns that 
delay the implementation of large-scale human studies. More common methodologies involve 
genome wide association studies, gene expression profiling, and the candidate gene approach.  
Most molecular studies have focused on targeting three major categories of gene 
therapies: the nitric oxide system, growth factors, and K+ ion channel mechanisms. Although 
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candidate gene studies in humans have revealed multiple genetic variants potentially associated 
with ED, few results have been consistently replicated. Many of these studies rely on small 
samples composed of different ethnic backgrounds, which is problematic given that certain 
implicated polymorphisms occur at different frequencies across ethnic groups. For example, 
while some studies have found the 7G894T polymorphism of the endothelial nitric oxide synthase 
gene to be an independent factor for ED in Mexican (Rosas-Vargas et al., 2004), Turkish (Erol et 
al., 2009), and Taiwanese samples (Lee et al. 2007), other studies have found no role for this 
polymorphism in Brazilian (Andersen, Guindalini, Santos-Silva, Bittencourt, & Tufik, 2010) or 
German samples (Eisenhardt et al., 2010). What to make of these conflicting findings is puzzling. 
Future research with increased power and more generalizable samples are warranted. 
Despite the limited interventions that have resulted from molecular studies thus far, 
advances in genetic technology as well as our understanding of the genome suggest that the future 
of the field will be promising. Lopushnyan and Chitaley (2012) hypothesized that genetic studies 
of ED will ultimately reveal two genetic categories: (1) those that contribute to the development 
of ED or protect against it (2) and those that are markers for it. Findings from both categories will 
facilitate novel approaches to prevention, diagnosis, and treatment.  
In conclusion, the results from the present study suggest that genes significantly influence 
ED, though this influence appears to decline over time. In contrast, the importance of unique 
environmental factors appears to increase as we age. Future studies are warranted to further 
explore the mechanisms that comprise the genetic component of ED. ED is a highly important 
condition to characterize given its role in predicting future cardiovascular morbidity and 
mortality. 
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Table 1.1. Repeated measures ANOVA on demographic and health variables from age 55 
(VETSA 1) to age 60 (VETSA 2). 
Risk Factor VETSA 1 VETSA 2 t p 
Age, M(SD) 55.5 (2.6) 61.2 (2.6) -6.9 <.001 
ED, (%) 48 65 -5.5 <.001 
Hypertension, (%) 60 65.9 -3.2 .001 
High Cholesterol, (%)** 31 55.4 -10.5 <.001 
Pack Years, M (SD) 18.7 (22.9) 20.1 (24.8) -11.3 <.001 
CVD, (%) 16.5 21.3 3.8 <.001 
Diabetes, (%) 10.3 18.1 5.33 <.001 
Body Mass Index 29.4 30.0 -6.9 <.001 
Depression: Total CES-D score, M 
(SD) 
8.8 (8.4) 8.7 (12.0) .35 .73 
Depression, MDD cut-off on C-ESD, 
% 
15.0 17.2 -1.4 .16 
Note**: High Cholesterol was measured differently at VETSA 1 and VETSA 2. At VETSA 1, 
high cholesterol was ascribed to participants if they were taking cholesterol-lowering 
medications. At VETSA 2, high cholesterol was ascribed if they endorsed a high cholesterol 
diagnosis, or had abnormal cholesterol levels during our blood draw. 
22	  
	  
 
Ta
bl
e 
1.
2.
 M
od
el
 fi
t s
ta
tis
tic
s c
om
pa
rin
g 
go
od
ne
ss
 o
f f
it 
ac
ro
ss
 d
iff
er
en
t m
od
el
s 
A
IC
	  
-1
11
0.
23
	  
0.
49
 
-0
.0
03
 
-0
.6
38
 
-1
.5
2 
-2
.6
4 
-1
.4
9 
-0
.0
02
 
-3
.4
9 
-3
.4
1 
-5
.4
1 
-7
.4
 
16
.5
7 
P 
V
al
ue
	   	  
0.
12
 
1.
0 
0.
19
 
0.
29
 
0.
34
 
0.
48
 
1.
0 
0.
78
 
0.
75
 
0.
9 
0.
96
 
0 
Δ (D
F)
	   	   1 1 2 2 3 1 1 2 2 3 4 4 
(Δ
-2
LL
)	   	  
2.
49
 
0 3.
36
 
2.
49
 
3.
36
 
0.
51
 
0 0.
51
 
0.
59
 
0.
59
 
0.
6 
24
.5
7 
DF	   1421	   1422 1422 1423 1423 1424 1422 1422 1423 1423 1424 1425 1425 
-­‐2LL	   1731
.7
7	  
17
34
.2
5 
17
31
.7
6 
17
35
.1
3 
17
34
.2
5 
17
35
.1
3 
17
32
.2
8 
17
31
.7
6 
17
32
.2
8 
17
32
.3
5 
17
32
.3
5 
17
32
.3
6 
17
56
.3
3 
M
od
el
 D
es
cr
ip
tio
n	  
Fu
ll 
M
od
el
	  
G
en
et
ic
 c
or
re
la
tio
n 
fix
ed
 to
 b
e 
ze
ro
 
 G
en
et
ic
 c
or
re
la
tio
n 
fix
ed
 to
 b
e 
1.
0.
 
G
en
et
ic
 v
ar
ia
nc
e 
at
 V
1 
an
d 
ge
ne
tic
 c
or
re
la
tio
n 
se
t t
o 
be
 z
er
o.
 
G
en
et
ic
 v
ar
ia
nc
e 
at
 V
2 
an
d 
ge
ne
tic
 c
or
re
la
tio
n 
se
t t
o 
be
 z
er
o.
 
G
en
et
ic
 v
ar
ia
nc
e 
at
 V
1 
an
d 
V
2 
an
d 
ge
ne
tic
 c
or
re
la
tio
n 
se
t t
o 
be
 z
er
o.
 
C
om
m
on
 e
nv
iro
nm
en
t c
or
re
la
tio
n 
se
t t
o 
be
 z
er
o.
 
C
om
m
on
 e
nv
iro
nm
en
t c
or
re
la
tio
n 
se
t t
o 
be
 1
.0
. 
C
om
m
on
 e
nv
iro
nm
en
t v
ar
ia
nc
e 
at
 V
1 
an
d 
co
m
m
on
 e
nv
iro
nm
en
t c
or
re
la
tio
n 
se
t t
o 
be
 z
er
o.
 
C
om
m
on
 e
nv
iro
nm
en
t v
ar
ia
nc
e 
at
 V
2 
an
d 
en
vi
ro
nm
en
t c
or
re
la
tio
n 
se
t t
o 
be
 
ze
ro
. 
C
om
m
on
 e
nv
iro
nm
en
t a
t V
1 
an
d 
V
2 
an
d 
co
m
m
on
 e
nv
iro
nm
en
t c
or
re
la
tio
n 
se
t t
o 
be
 z
er
o.
 
C
om
m
on
 e
nv
ir
on
m
en
t a
t V
1 
an
d 
V
2 
an
d 
co
m
m
on
 e
nv
ir
on
m
en
t 
co
rr
el
at
io
n 
se
t t
o 
be
 z
er
o,
 a
nd
 g
en
et
ic
 c
or
re
la
tio
n 
se
t t
o 
be
 1
.0
. 
C
om
m
on
 e
nv
iro
nm
en
t a
t V
1,
 g
en
et
ic
 in
flu
en
ce
 a
t V
2,
 c
om
m
on
 e
nv
iro
nm
en
t 
co
rr
el
at
io
n,
 a
nd
 g
en
et
ic
 c
or
re
la
tio
n 
fix
ed
 a
t z
er
o.
 
M
od
el
	  
M
od
el
 1
 
M
od
el
 2
 
M
od
el
 3
 
M
od
el
 4
 
M
od
el
 5
 
M
od
el
 6
 
M
od
el
 7
 
M
od
el
 8
 
M
od
el
 9
 
M
od
el
 1
0 
M
od
el
 1
1 
M
od
el
 1
2 
M
od
el
 1
3 
	  
23	  
	  	  	  	   	  	  
C 
A 
A 
C 
E 
E 
ED	  age
	   55 
ED	  age
	   60 
.6
9 
e2
=.
47
 
(0
.3
1,
 0
.6
6)
 c2
=0
 
 .7
3 
h2
=.
53
 
(0
.3
4,
0 
.6
9)
 
.5
7 
h2
=.
33
 
(0
.1
6,
0 
.5
2)
 
c2
=0
 
.8
2 
e2
=.
67
 
(0
.4
8,
 0
.8
4)
 
r g
=1
.0
 
r e
=.
44
 
(.2
4,
 .6
2)
 r
c=
0.
0 
Fi
gu
re
 1
.1
 B
iv
ar
ia
te
 c
or
re
la
te
d 
fa
ct
or
s m
od
el
 fo
r S
ex
ua
l H
ea
lth
 In
ve
nt
or
y 
fo
r M
en
 (S
H
IM
) s
co
re
s 
at
 b
as
el
in
e 
(a
ge
 5
5)
 a
nd
 a
t 
fo
llo
w
-u
p 
(a
ge
 6
0)
, d
ur
in
g 
th
e 
V
ie
tn
am
 E
ra
 T
w
in
 S
tu
dy
 o
f A
gi
ng
 I 
an
d 
II
, r
es
pe
ct
iv
el
y.
 A
 =
 a
dd
iti
ve
 g
en
et
ic
 fa
ct
or
s;
 C
 =
 sh
ar
ed
 
fa
m
ily
 e
nv
iro
nm
en
t; 
E 
= 
no
ns
ha
re
d 
en
vi
ro
nm
en
t; 
rG
 =
 g
en
et
ic
 c
or
re
la
tio
n;
 rC
 =
sh
ar
ed
 e
nv
iro
nm
en
t c
or
re
la
tio
n;
 rE
 =
 n
on
sh
ar
ed
 
en
vi
ro
nm
en
t c
or
re
la
tio
n.
 T
he
 d
ia
gr
am
 s
ho
w
s p
at
h 
co
ef
fic
ie
nt
s,
 w
ith
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
s i
n 
pa
re
nt
he
se
s;
 v
al
ue
s i
n 
br
ac
ke
ts
 
24	  
	  
	  
	  
	  
 
CHAPTER II: 
Elevated Inflammation and Erectile Dysfunction: A 
Comparison of Pro-Inflammatory Serum Proteins 
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INTRODUCTION 
Diminished sexual function later in the lifespan has long been assumed a byproduct of the 
aging process. Empirical evidence supporting the link between age and sexual dysfunction is well 
established, with reports dating back to Kinsey’s landmark studies in 1948 (Kinsey, 1948). The 
Kinsey studies discovered that sexual dysfunction prevalence increases by each decade. 
Specifically, they found ED prevalence to be 27% at age 70, 55% at age 75, and 75% at age 89.  
 The Baltimore Longitudinal Study of Aging replicated this trend, citing erectile 
difficulties in 8% of men in their 50s, 25% of men in their 60s, 55% of men in their 70s, and 75% 
of men in their 80s (Morley, 1986). In the Massachusetts Male Aging Study (a large community-
based observational survey of men aged 40–70 years) the prevalence overall of erectile 
dysfunction was 52% in men aged 40–70 years. However, they discovered that a 70 year-old man 
was three times more likely to have ED than a 40 year-old man (Feldman, 1994). This close 
association with age is becoming increasingly important as the “graying of America” comes to 
the forefront. For many men, decreases in sexual function are associated with decrements in 
quality of life (Davis, Binik, Amsel, & Carrier, 2013; Manolis & Doumas, 2008). 
Although these sexual declines are well documented, less is known about when and why 
sexual changes emerge and if measures can be taken to slow or the delay the progression of 
sexual dysfunction. It is likely not aging per se that is associated with sexual change, but with 
correlates of aging: late-life diseases, changes in sex hormones, increased medication usage, 
declining physical strength, and partner availability (Gades et al., 2009). 
 
CARDIOVASCULAR DISEASE AND ED 
One such variable of interest is vascular disease. Bortolotti (1997) reviewed four studies 
involving 1,476 men with heart disease, myocardial infarction or vascular surgery and found 
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incidences of ED ranging from 39–64% in each patient group. Hodges (2007) found that men 
with ED were at increased risk of developing cardiovascular diseases in the impending 3-5 years. 
Others have replicated this finding (Baumhäkel & Böhm, 2007; Jackson et al., 2010), with some 
studies showing that ED significantly predicts CVD as far as a decade away (Ponholzer, Temml, 
Obermayr, Wehrberger, & Madersbacher, 2005). Montorsi and colleagues (2005) hypothesized 
that this phenomenon occurs because ED is a manifestation of subclinical vascular dysfunction 
and represents a precursor to adverse cardiovascular events. Specifically, they developed the 
“artery size hypothesis”, which at its essence states that because penile arteries are smaller than 
carotid or coronary arteries, they are the first arteries at risk in early stage vascular dysfunction 
and atherosclerosis.  
In this regard, ED is a fascinating disorder because it provides a window of time between 
ED onset and overt cardiovascular illness for medical intervention to be introduced (Miner et al., 
2009). Given that CVD is the leading cause of morbidity and mortality globally (World Health 
Organization, 2010), continued research on ED is warranted to explore how CVD develops and 
identify opportunities to slow or delay the disease process.  
 
INFLAMMATION, CARDIOVASCULAR DISEASE, AND ERECTILE DYSFUNCTION 
It is known that inflammation plays an important role in the progression of vascular 
disease (Spagnoli, Bonanno, Sangiorgi, & Mauriello, 2007) and relationships between inflammation 
and ED have been proposed (Vlachopoulos, Rokkas, Ioakeimidis, & Stefanadis, 2007). There is a 
need to further explore how inflammatory biomarkers are associated with ED as this may enhance 
our ability to identify men who are at highest cardiovascular risk. Over the last dozen years, 
appreciation of the role of inflammation in CVD has burgeoned (Libby, 2006). Inflammation is 
involved in every stage of atherosclerosis, propelling the formation, progression, and ultimately 
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medical complication of atherosclerotic plaques (e.g. infarction, aneurysm) in CVD (Libby, 
2002). Accumulating data suggest that that inflammation levels can reveal predictive and 
prognostic information, particularly in men over 50 years old with a family history of CVD or 
men who themselves are at intermediate CVD risk (for example, men with ED) (Davidson et al., 
2011). In this sense, studying inflammation in the context of ED is important because it allows us 
to examine the role inflammation plays in the progression of subclinical disease. 
 
INFLAMMATORY MARKERS: SERUM PROTEIN COMPOSITION 
Of particular interest in this regard is the assessment of serum protein composition, which 
has been studied as a predictor of incident CVD and CVD mortality. The serum proteins are 
mainly divided into 2 groups, albumin and globulins, both of which are believed to play a pivotal 
role in the inflammatory process.  
Though not viewed as conventional vascular risk factors (like, for example, hypertension, 
hyperlipidemia, smoking, obesity) or as well studied as other biomarkers (e.g. C-Reactive 
Protein, Interleukin-6, Homocysteine, etc.), accumulating evidence has shown that albumin and 
globulin may be highly relevant to the diagnosis and management of inflammatory conditions. 
For example, in a study by Leyva and colleagues (1998) that used factor analysis to predict 
incident coronary heart disease (CHD), the authors discovered that while the metabolic syndrome 
explained the greatest proportion of the variance, the second most prominent factor comprised 
elevated globulin levels and white cell count and reduced albumin levels. They hypothesized that 
this factor reflected subclinical inflammation levels. In a follow-up study on this cohort, 
Godsland and colleagues (2004) reported that this “subclinical inflammation” factor had become 
more predictive of incident CHD than the metabolic syndrome factor. Further, they found that 
28	  
	  
these simple indices of inflammation were able to predict CHD mortality as strongly as 
cholesterol levels.  
More recently, Fischer and colleagues (2014) discovered that a latent inflammation score 
comprising four biomarkers (one of which was serum albumin, another being a globulin protein) 
predicted the risk of all-cause mortality after adjusting for conventional risk factors. In this study, 
participants with an inflammation score in the top 20% were 19 times more likely to die within 
five years than individuals with a score in the bottom 20%.  
Though research on albumin and globulin is still in its nascence, these studies suggest 
that albumin and globulin may offer promising predictive utility for incident CVD, above and 
beyond what conventional vascular risk factors currently afford. In addition to these findings, 
other studies have noted that albumin and globulin assays are also convenient and relatively 
inexpensive compared to other blood assays, which would make them especially useful in chronic 
conditions like CVD that require routine management (Du et al., 2014). Given this, future studies 
on the topic are warranted to better elucidate how these protein markers are implicated in early 
stages of the disease process. 	  
SERUM PROTEINS: ALBUMIN 
Serum albumin is a negative marker of the acute-phase inflammatory response. Albumin 
levels fall in response to tissue injury, infection, and inflammation.  Cytokines such as 
interleukin-6, which are high in acute or chronic inflammation, decrease serum albumin levels 
(Ramadori, Van Damme, Rieder, & Meyer zum Büschenfelde, 1988). The first study looking at 
albumin in relation to CVD occurred in 1989 (Phillips, Shaper, & Whincup, 1989).  In this study, 
a one standard deviation decrease in albumin was associated with a 40% increased risk for CVD 
mortality. In fact, albumin was as strongly associated with CVD mortality as cigarette smoking. 
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Surprised by the findings, the investigators described this result as "serendipitous," stating that 
this may be a classic case of false positive given that they had no prior hypotheses about albumin. 
However, as discussed below, it was not long before other studies on albumin emerged and 
replicated these findings.  
In one prospective study of coronary heart disease, a comparison of individuals with low 
versus high albumin has yielded a combined risk ratio for coronary heart disease of 1.5 (1.3–1.7) 
(Danesh, Collins, Appleby, & Peto, 1998). Schalk and colleagues (2006) found that declines in 
serum albumin over time, even with levels in the normal range, were associated with increased 
risk of incident CVD. Relatedly, several studies have found that low concentration of serum 
albumin is related to frailty (Schalk, Visser, Deeg, & Bouter, 2004), impairment in activities of 
daily living (Okamura et al., 2008), and greater all-cause mortality (Mehrotra et al., 2011). Even 
within the normal range, low serum albumin levels may be associated with increased mortality 
(Philips et al., 1989). 
Despite these strong results, the literature is plagued with mixed findings. In contrast to 
these studies, several others have reported no significant association between albumin and health 
outcomes. For example, Folsom and colleagues (1995) found no association between albumin and 
atherosclerosis, but rather indicated that albumin is more associated with diabetes. Djoussé et al. 
(2003) found no association between albumin and carotid atherosclerosis in either men or women. 
Others have called the significance of albumin into question, and as described below, have 
implicated the globulin fraction of protein as the inflammatory culprit (Darne, Ducimetiere, & 
Guize, 1990; I. Godsland et al., 2011). 
 
SERUM PROTEINS: GLOBULIN 
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Unlike albumin, globulin is not typically measured directly. Globulin levels are derived 
by calculating the difference between the total protein level and the albumin level. The globulins 
are a group of about 60 different proteins that are part of the immune system (e.g. antibodies), 
which help to fight or prevent infections. They also serve as carrier proteins for hormones. One of 
the most extensively studied globulins with regard to cardiovascular disease is the sex-hormone 
binding globulin (SHBG). SHBG is a testosterone transport protein that affects the circulating 
levels of free testosterone. It has been linked to the metabolic syndrome, cardiovascular risk, and 
diabetes (Li, Ford, Li, Giles, & Liu, 2010). And, in contrast to albumin levels, which drop during 
inflammation, globulin levels rise. Elevated globulin serves as a marker of chronic inflammation 
and reflects a cumulative exposure of various proinflammatory cytokines (Godsland et al., 2011). 
Somewhat surprisingly, there are quite limited data on globulin’s role in CVD 
development. In fact, most studies investigating globulin and inflammation in CVD have 
analyzed globulin in relation to albumin (via the albumin/globulin ratio, discussed in greater 
detail below) and not as an independent predictor in its own right. Some have argued that the 
increased morbidity and mortality associated with reduced albumin is a spurious result, and is 
actually due to elevated globulin levels. If albumin levels vary inversely with globulin in order to 
maintain total protein concentrations (Chow, 1947), it is plausible that the significant findings 
with regard to low albumin levels may simply be a byproduct of elevated globulin.  
Darne et al. (1990) presented data from a study of 18,333 men and 9,351 women that 
showed that albumin was strongly (and inversely) related to cardiovascular and cancer mortality 
over 10 years. However, when accounting for globulin, the effect of albumin disappeared and 
death rates were significantly and directly related to globulin levels. Godsland and colleagues 
(2011) also found an exceptionally strong relationship between elevated globulin levels and 
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incident CVD, and agreed that it may be the globulin fraction of the total protein count that is the 
active index. 
In contrast, Phillips et al. (1989) published a report showing that in their sample, globulin 
was not significantly related to mortality after controlling for albumin.  Other studies have 
published similar findings in support of albumin as a significant predictor of cardiovascular 
morbidity and mortality, and against globulin (Arques, Roux, Stolidi, Gelisse, & Ambrosi, 2011; 
Weijenberg, Feskens, Souverijn, & Kromhout, 1997). Appeasing both sides of the argument, 
Sweetnam and Yarnell (1990) reported that in their prospective study of mortality, both low 
albumin and high globulin were independently related to mortality. 
 
ALBUMIN AND GLOBULIN: A COMBINED APPROACH 
In addition to analyzing albumin and globulin as independent predictors, there is 
emerging evidence to suggest that the albumin/globulin ratio (AGR) confers unique prognostic 
information about one’s inflammatory state, and may possibly be a more powerful index of 
inflammation than either protein fraction in isolation. Azab and colleagues have published 
numerous reports showing that the AGR is an independent predictor of mortality in breast cancer 
patients (B. N. Azab et al., 2013), colorectal cancer patients (B. Azab, S. Kedia, et al., 2013), and 
patients with non-ST-segment elevation myocardial infarction (B. Azab, J. Bibawy, et al., 2013). 
To complicate matters further, Wang et al. (2012) found that including serum albumin 
and globulin as an interaction term (albumin x globulin) (AGI) had a synergistic effect on 
increasing the odds of having coronary heart disease, such that low albumin and low globulin 
were associated with an odds ratio of 16.03 (CI 9.66-26.59) of having CHD when compared to 
other low/high albumin and globulin combinations. In contrast to previous studies (Darne et al., 
1990; Godsland et al., 2011), they found that low levels – rather than high levels – of globulin 
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were a significant predictor of coronary heart disease. They acknowledged the dearth of research 
on globulin specifically, and suggested that further research be done to better characterize this 
protein group. 
 
BACKGROUND SUMMARY 
Despite the accumulating data suggesting that altered albumin and/or globulin levels may 
be implicated in the inflammatory process, the biological mechanism linking these variables to 
increased cardiovascular morbidity and mortality remains unknown. For example, some 
hypothesize that these proteins are simply markers of inflammation, and their levels may be 
altered because of generally increased vascular permeability in CVD resulting from tissue 
damage (Kuller et al., 1991). Others have posited that they may have more of an active role in the 
disease process. Albumin may bind to free fatty acids, and thereby inhibit platelet aggregation 
and thrombosis (Jørgensen & Stoffersen, 1980). Furthermore, albumin may act as an indirect 
antioxidant through its specific binding to metals and by means of its ability to scavenge peroxyl 
radicals (Doweiko et al., 1994; Roche et al., 2008). Globulins play a significant role in the 
immune system (Mestecky et al., 1987), and compromised immune functioning has been 
implicated in the inflammatory and atherosclerotic disease process (Frostegård, 2013). Without a 
clear understanding of the mechanistic roles that albumin and globulin play in inflammation, it is 
not surprising that the literature has had difficulty reconciling the mixed findings on these protein 
groups in CVD morbidity and mortality. 
Though most studies look at these variables in the context of extant CVD, there are 
appreciably fewer studies looking at how these markers relate to ED. Very few studies have been 
published on the relationship between albumin and erectile dysfunction. Chuang and colleagues 
(2012) reported that in a diabetic sample, low serum albumin was associated with modestly 
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increased risk of having ED, with an odds ratio of .31 (95% CI: .11 - .85). Yu et al. (2010) have 
also reported higher prevalence of albuminuria (abnormal levels of albumin secreted in urine) in 
men with ED (no ED: 16.3%, mild to moderate ED: 34.4%, moderate to severe ED: 54.5%). 
Given the paucity of data looking at globulin’s role in CVD, it may not be surprising that, to my 
knowledge, there is no research to date looking at globulin’s role in ED. Further, no studies on 
AGR or the AGI in ED have been found. 
Taken together, findings on the relationship between albumin and globulin with CVD 
remain equivocal. Convincing data exist for both protein fractions and it seems plausible that both 
play a role at some part of the development and progression of vasculopathic processes. Much of 
the current literature has examined these proteins and their relationship to CVD and cancer 
mortality, and a lesser focus has been placed on analyzing these hematic markers in the early 
stages of vascular disease. Because ED is widely acknowledged as a harbinger of adverse 
cardiovascular events (Miner et al., 2009), comparing and contrasting albumin and globulin in the 
context of ED may serve to enhance our understanding of CVD development and may help 
identify paths to intervention. Further, understanding the inflammatory cascades implicated in ED 
may aid in ED diagnosis and management. ED is a prevalent condition that impacts quality of life 
(Litwin, 1998). Better understanding of ED and its sequelae are warranted. The goal of the 
present study is to assess the relationship between erectile functioning and four indices of 
inflammation: albumin, globulin, AGR, and the AGI.  If protein levels are associated with ED, 
this may suggest that albumin and/or globulin measurement might be useful as a screener or 
predictor of the presence and severity of ED. 
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METHODS 
Participants 
The present study utilizes data from the second wave of the Vietnam Era Twin Study of 
Aging (VETSA), a longitudinal study of cognition and aging beginning in midlife (Kremen et al., 
2006). VETSA participants are from the Vietnam Era Twin Registry (VETR), a nationally 
representative sample of male–male twin pairs who served in the U.S. military sometime between 
1965 and 1975. Most did not serve in combat. Detailed descriptions of the VETR and 
ascertainment methods have been previously reported (Kremen, Franz, & Lyons, 2012; Kremen 
et al., 2006). VETSA participants are similar to the general population of middle-aged American 
men in terms of socioeconomic status and health characteristics (Kremen et al., 2012). 
Participants traveled to laboratories at Boston University or the University of California, San 
Diego. The study was approved by local Institutional Review Boards.   
Given our interest in examining the relationship between inflammation and ED as a 
subclinical harbinger of vascular disease, individuals were excluded if they were already 
diagnosed with heart disease (angina pectoris, peripheral vascular disease, myocardial infarction, 
heart failure, stent placement or heart surgery). This is in line with other studies exploring the 
predictive nature of ED (Thompson et al., 2005). Participants were also excluded if they currently 
have cancer, given that there is a literature on the relationship between cancer and abnormal 
protein levels (Azab et al., 2013). History of any of these medical conditions was based on 
participants’ endorsement when asked if they had ever been told by a doctor that they had the 
condition. Participants were excluded if they had not attempted sex during the past month, as this 
is the timeframe the erectile function measure queries about. Participants were also excluded if 
they did not complete the erectile functioning measure or did not complete the blood assay. With 
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these exclusions, the final sample for the analyses reported here comprised 388 men with an 
average age of 60.9 years (SD=2.4; range= 57-65). 
 
Measures   
Sexual Functioning Assessment: 
Erectile function was assessed with the International Index of Erectile Function-5 (IIEF-
5) (also referred to as the Sexual Health Inventory for Men (Shim et al.)) (Rosen et al., 1999), a 
well-validated self-report questionnaire. Responses to each of the five items on the SHIM, which 
are based on a rating scale from 0 to 5 or from 1 to 5 (depending on the item), are summed to 
arrive at a total score that can range from 1 to 25, with higher scores indicating better sexual 
health. ED is classified as mild (17-21), mild to moderate (12-16), moderate (8-11), and complete 
ED (1-7). Scores ranging from 22-25 suggest no clinically significant erectile difficulties. 
 
Serum Assay: 
A fasting blood draw was conducted between 08:00–09:00 A.M. (after an overnight fast). 
Plasma was separated by centrifugation (3000g at 4°C for 15 min), then placed in aliquots and 
stored at −70°C prior to being picked up by Quest Diagnostic Laboratories (Cambridge, MA). 
Serum protein markers were analyzed by spectrophotometry biochemical analyzer. 
Four indices of inflammation were analyzed in the present study: albumin, globulin, 
AGR, and the AGI. Albumin is directly measured; the globulin fraction, AGR, and AGI are 
calculated. Globulin is derived by the equation total proteins – albumin. AGR is equal to 
albumin/(total protein – albumin). And, in accordance with the procedure by Wang et al., (2013), 
AGI was equal to albumin multiplied by globulin.   
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C-Reactive Protein, another inflammatory protein and a conventional vascular risk factor, 
was used as a covariate in the present analyses. It was also collected during the fasting blood 
draw. Higher values suggest higher risk for inflammation and heart disease, with the cut-off of 
3.0 mg/L generally considered high risk. 
 
Risk Factor Covariates 
Participants were also assessed for a variety of measures that could be related to sexual 
dysfunction, including age, body mass index (BMI), smoking, high cholesterol, hypertension, and 
depressive symptoms. Hypertension was ascribed to participants if they were taking 
antihypertensive medications, endorsed that a physician had given them this diagnosis, or had 
blood pressure on the day of testing above 140/90. High cholesterol was ascribed to participants 
who endorsed that a physician had diagnosed them as having hypercholesterolemia, or had 
abnormal cholesterol levels on the testing day (which was included in the fasting blood draw) 
(LDL: > 160 mg/dL; HDL: <40 mg/dL; Total cholesterol: >240 mg/dL). Depressive symptoms 
were measured by the Center for Epidemiologic Studies-Depression Scale (CES-D) (Radloff, 
1977).  
Because certain questions were removed from our baseline evaluation to our follow-up, 
our assessment of smoking changed. At our baseline assessment (VETSA 1), men were queried 
about their smoking history, including when they began smoking and how many cigarettes they 
were smoking per day. From that, a pack years variable (packs of cigarettes smoked per day x 
years smoked) was calculated, and we were able to determine how many pack years each 
participant had at VETSA 1. Participants were not queried about their current smoking frequency 
at our follow-up assessment (VETSA 2). To estimate pack years at VETSA 2, we made the 
assumption that all men smoking at VETSA 1 would still be smoking at VETSA 2, and all men 
37	  
	  
who had quit smoking by VETSA 1 would still be abstaining at VETSA 2. For men who 
endorsed being current smokers at VETSA 1, we calculated a “pack years rate” (pack years at 
VETSA 1 / number of years smoked) and multiplied this rate by the numbers of year they had 
smoked, now extending through VETSA 2. For example, if a man had 30 pack years (e.g., 15 
years of smoking 2 packs per day) at VETSA 1 and endorsed being a current smoker, 5 years 
later when he came in for his VETSA 2 evaluation, his new estimated pack years would be 40 (30 
pack years / 15 years of smoking = a rate of 2 pack years/ year; 2 pack years/ year * 20 years of 
smoking [15 years through VETSA 1 plus 5 years to VETSA 2]). If a man had stopped smoking 
by VETSA 1, his pack years variable at VETSA 2 was equal to his pack years value at the 
baseline evaluation. In other words, if a participant had 30 pack years at VETSA 1 but quit 
smoking prior to his VETSA 1 assessment, it was presumed that he had acquired no more pack 
years and his estimated pack years at VETSA 2 would remain as 30. Participants who endorsed 
never smoking in their lifetime were given a pack years of zero.  
 
Statistical Methods 
 The analyses will be non-twin analyses, i.e., individuals, not twin pairs, were the unit of 
analysis. All analyses adjusted for the clustering of twins within pairs with mixed modeling in 
SPSS 19.  We began with descriptive statistics of prevalence of ED and other risk factors. Next, 
univariate mixed models were used to determine if the four biomarkers were significantly 
associated with ED. Following this, a second stage of mixed models was conducted to determine 
if the biomarkers were independently associated with ED when controlling for age, BMI, 
smoking, depressive symptoms, hypertension, and high cholesterol. 
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RESULTS 
 Prevalence estimates for demographic variables and cardiovascular risk factors in the ED 
and non-ED groups are presented in Table 2.1. Intriguingly, even in a sample free from overt 
cardiovascular disease, 26.3% of the sample qualified for an ED diagnosis based on their self-
report responses.  When stratified by ED severity, 68.6% of the sample reported no ED (n=266), 
17% reported mild ED (n=66), 4.1% reported mild-to-moderate ED (n=16), 2.6% reported 
moderate ED (n=10), and 7.7% reported complete ED (n=30). Table 2.2 presents the descriptive 
statistics of the protein indices. 
 In the first stage of univariate analysis, ED was significantly associated with albumin 
(F[1, 385.9]=6.3, p=.012), such that lower albumin levels were significantly associated with 
increasing ED severity (Table 2.3). Globulin also demonstrated a significant relationship with 
ED, with higher globulin levels associated with increased ED severity (F[1, 385.1]= 8.1, p=.005). 
AGR demonstrated the strongest relationship with ED (F[1, 383.5]=8.47, p=.004), with lower 
AGR significantly associated with poorer erectile functioning. Lastly, the relationship between 
ED and AGI did not reach statistical significance. Given this, AGI was excluded from the 
following series of analyses in which the association between ED and protein indices were 
explored in the context of conventional vascular risk factors.  
 The next series of models controlled for hypertension, cholesterol, smoking, CRP, BMI, 
depression, and age. ED maintained its significant relationship with albumin (p=.03) (Table 2.4), 
globulin (p=.009) (Table 2.5), and AGR (.009) (Table 2.6). The protein parameters were also 
more strongly associated with ED severity than the other risk factors analyzed, with the exception 
of depression being slightly stronger than albumin.  
 The final model included both albumin and globulin as predictor variables, along with the 
ED risk factors described above. In these analyses, globulin remained significantly associated 
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with ED severity (p=.02), whereas albumin was pushed just above the threshold for significance 
(p=.06) (Table 2.7). 
 
DISCUSSION 
The novel findings from the present study indicate that the AGR, albumin, and globulin 
protein levels are significantly associated with erectile difficulties. The protein levels maintained 
significant relationships with ED after taking into account other risk factors. These results are 
particularly intriguing because AGR and globulin levels were found to be more strongly 
associated with ED than conventional vascular risk factors (i.e., hypertension, depression, high 
cholesterol, BMI, smoking, and advanced age). A similar pattern was seen with albumin, though 
depressive symptoms were slightly more strongly associated with ED than albumin levels. To my 
knowledge, this is the first study demonstrating a significant relationship between globulin and 
AGR with ED.  
It is well known that inflammation contributes to the progression of vascular disease, and 
vascular disease is the primary cause of ED. Given this, our findings are consistent with the 
literature in that albumin, globulin, and AGR (markers of inflammation) are significantly 
associated with ED severity.  
The literature is currently mixed with regard to whether albumin or globulin (or both) are 
associated with CVD. Our findings suggest that both albumin and globulin are playing at least 
some role in CVD development, as men with reduced albumin and elevated globulin levels are at 
increased risk of ED – an established risk factor for future cardiovascular events. When including 
both albumin and globulin into the regression model, only globulin survived as an independent 
predictor (though albumin was at trend-level). Although it is plausible that in a larger sample, 
albumin would have maintained its significant relationship with ED, our findings are consistent 
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with several studies that have found a significant association between globulin – not albumin – 
and CVD incidence (Godsland et al., 2011; Darne et al., 1990).  
There has been a recent emphasis on AGR as an important indicator of inflammatory 
status. Consistent with recent studies by Azab and colleagues (B Azab et al., 2013; B. Azab et al., 
2013; B. N. Azab et al., 2013), AGR proved to be strongly associated with severity of erectile 
difficulties. AGR and globulin appeared to be similarly strong predictors of ED, with maybe a 
slight advantage toward AGR. Given this, it is unclear from our findings if AGR conveys unique 
information about inflammatory status above and beyond globulin alone. Nevertheless, the fact 
that AGR was so strongly associated with ED – more so than hypertension, high cholesterol, age, 
smoking, BMI, and depression – suggests that more studies on the predictive utility of AGR are 
warranted. Because men with ED are at increased risk of future cardiovascular disease in 3-5 
years (Hodges et al., 2007), our findings suggest that elevated AGR will likely be associated with 
CVD incidence.  
Unlike other protein parameters in the present analyses, AGI was not independently 
associated with ED severity. This finding is in contrast to the report by Wang et al. (2012), which 
found that there was a synergistic effect of having low globulin and low albumin such that this 
combination was associated with a 16x greater likelihood of coronary heart disease. Important 
differences between the present study and that by Wang and colleagues include: different 
participant population, less severe vascular pathology in the present study, and wider age range in 
their study (50-74 in Wang et al.’s study, 57-65 in the present analyses). 
It is not clear whether reduced albumin and elevated serum globulin levels and AGR are 
non-specific, prognostic variables marking for subclinical disease, or part of the causal 
mechanism leading to ED. The findings from this study cannot determine what role these proteins 
play in the development of ED. While previous studies have documented that these indices are 
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associated with serious cardiovascular illnesses, our findings suggest these protein parameters are 
significantly associated with CVD risk early on in the disease process. It is plausible that the 
relationships between albumin, globulin, and AGR with ED are indirect, with albumin and/or 
globulin levels being a byproduct of noxious biological changes that occur in the process of 
vascular dysfunction. It is also plausible that globulin is playing an active role in atherosclerotic 
progression, and increasing levels of globulin directly result in more vascular damage. Similarly, 
low serum albumin may increase atherosclerotic risk through reduced defense oxidative stress 
(Sitar et al., 2013).  
Consistent with numerous studies reporting a significant relationship between albumin 
and CVD (Schalk et al., 2006), cancer (Lai et al., 2011), frailty (Schalk et al., 2004), and 
mortality (Fischer et al., 2014), our study found a significant relationship between albumin and 
ED severity. In contrast to many of these studies, our findings suggested that globulin is more 
strongly associated to inflammation that albumin. Some important differences exist between the 
present findings and these previous studies. In our study, we looked at how albumin relates to a 
subclinical vascular disorder (i.e., ED) rather than the more serious clinical cardiovascular 
morbidities (e.g. heart failure, stroke, etc.) or mortality that were examined in other studies. The 
possibility remains that albumin will be more significantly associated with who progresses from 
ED to overt CVD. It is known that many men with ED will remit or progress over time (Travison 
et al., 2007), and it is possible that albumin levels will prove to be an important predictor of the 
progression of vascular disease in our at-risk sample. The relative contribution of albumin and 
globulin to atherosclerosis may vary over time, with one being more or less important at certain 
stages. Given that convincing data has emerged on both sides of the albumin vs. globulin debate, 
it seems likely that the issue should be conceptualized less as “which one is important”, and more 
as “when is each fraction important, and why?” 
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In our sample, ED was quite prevalent, with nearly 1/3 of men endorsing clinically 
significant erectile difficulties. This is particularly surprising given that men with overt CVD – a 
prominent cause of ED – were excluded. Because of this exclusion, this study does not offer a 
true prevalence statistic of ED in the general population, but rather demonstrates that ED is very 
common in older adults, even among those in good health.  
When considering our findings, some potential limitations of this study warrant 
consideration. One limitation is that pro-inflammatory markers were assessed at only one point in 
time, and by means of a single measurement. However, any measurement error likely did not vary 
between participants with and without ED, and the impact would probably bias results toward an 
apparent lack of a statistically significant association. Moreover, the consistency of our results 
with those of several other studies suggests that the findings are non-spurious. 
Another limitation concerns the fact that the serum globulins in the present study 
comprised all four types (a1, a2, beta, gamma-globulins). Consequently, we cannot determine 
which fraction of the globulin proteins was driving the relationship between globulin and ED. 
There is a literature that suggests that the gamma-globulins play a significant role in immune 
system functioning (Mestecky et al., 1987), and the immune system has shown to contribute 
substantially to cardiovascular health (Frostegard, 2013). Whether the correlation between 
globulin and CVD seen in the present study was largely driven by the anti-atherosclerotic effect 
of gamma-globulin deserves further investigation.  
 In some sense, another limitation concerns the fact that given our assessment of erectile 
functioning, our sample exclusively consisted of men. Of course ED is a male condition and 
requires an all-male sample. This fact naturally limits our ability to make assumptions about how 
serum proteins are related to CVD progression in women. While our findings suggest that 
globulin and AGR are implicated early in the CVD process, it is unclear whether CVD develops 
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identically in women. In fact, there is evidence to suggest that this may not be likely. Both 
Phillips and colleagues (1989) and Darne and colleagues (1990) presented data showing that 
globulin was strongly associated with cardiovascular mortality in men and not women. These 
proteins may have sex-specific relationships within different disorders.  
 In summary, while previous studies have demonstrated that elevated globulin, reduced 
albumin, and elevated AGR are significantly associated with extant CVD and cardiovascular 
mortality, our findings suggest that relationships are present in men with vascular disease at a 
subclinical level. These inflammatory markers were more strongly associated with ED severity 
than more conventional vascular risk factors. Overall, our findings comport well with the 
literature that shows that ED should be conceptualized as an inflammatory disorder 
(Vlachopoulos et al., 2007), and that albumin and globulin levels may independently predict CVD 
incidence (Sweetnam & Yarnell, 1990; Schalk et al., 2006; Godsland et al, 2011).  
 Prospective and mechanistic experimental studies are required to further elucidate the 
relationships among albumin, globulin, and CVD, and determine what factors may explain the 
mixed findings regarding albumin and globulin (e.g. disease stage, study sample, etc.). 
 In conclusion, in this study, high globulin, low albumin, and high AGR were 
independently associated with ED. In general, albumin, globulin, and the AGR were more 
strongly associated with erectile difficulties than more conventional vascular risk factors. The 
strongest relationships were found between globulin and AGR with ED. When including both 
albumin and globulin as predictors, the significant findings between ED and albumin washed 
away. Globulin remained a significant predictor, though the magnitude of the relationship 
between ED and globulin was diminished. This suggests that there may have been some influence 
of albumin levels on ED severity, despite the fact that the albumin-ED relationship did not 
maintain its statistical significance. 	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Table 2.1. Demographic and health characteristics of sample 
 M (SD) Range 
Age 60.9 (2.4) 57 - 65 
SHIM Score 21.0 (6.1) 1 - 25 
ED, n (%) 122 (31.4) N/A 
           No ED 266 (68.6) N/A 
           Mild ED, n (%) 66 (17) N/A 
           Mild-to-Moderate ED 16 (4.1) N/A 
          Moderate ED 10 (2.6) N/A 
          Complete ED 30 (7.7) N/A 
Hypertension*, n (%) 252 (63.8) N/A 
High Cholesterol*, n (%) 186 (47.1) N/A 
BMI 29.6 (4.7) 19.4 – 45.2 
Depression 6.06 (6.5) 0 – 39 
Pack Years 24.4 (36.4) 0-195 
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Table 2.2. Descriptive statistics of serum protein markers 
 M (SD) Range 
Albumin (g/dL) 4.5 (.278 3.5 – 5.3 
Globulin (g/dL) 2.6 (.36) 1.7 – 4.2 
AGR (g/dL) 1.8 (.27) .9 – 2.8 
AGI (g/dL) 11.7 (1.6) 7.7 – 18.2 
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Table 2.3. Mixed model analyses for ED in relation to Serum 
Protein Markers 
 
Erectile Dysfunction 
 β (SE) t F (df) p 
Albumin .77 (.3) 2.5 6.3 (1, 385.9) .012 
Globulin -.88 (.31) -2.9 8.1 (1, 385.1) .005 
AGR .9 (.31) 2.9 8.5 (1, 383.5) .004 
AGI -.45 (.31) -1.4 2.1 (1, 385.1) .15 
Abbreviations: AGR = Albumin/Globulin Ratio. AGI = 
Albumin*Globulin Interaction 
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Table 2.4. Mixed model analyses for ED in relation to globulin, demographic 
factors, and other health variables. 
  ED 
Globulin 
B (SE) -.85 (.33) 
t -2.61 
p .009 
Age 
B (SE) -.71 (.34) 
t -2.09 
p .04 
Hypertension 
B (SE) .5 (.66) 
t .75 
p .45 
High Cholesterol 
B (SE) -.41 (.64) 
t -.64 
p 53 
Depression 
B (SE) -.77 (.31) 
t -2.5 
p .01 
Pack Years 
B (SE) .01 (.32) 
t .03 
p .98 
CRP 
B (SE) .24 (.3) 
t .78 
p .44 
BMI 
B (SE) -.19 (.33) 
t 0.58 
p .56 
Presented estimates and significance levels represent each parameter’s 
influence after all other terms have been entered into the equation. Results 
are Type III Fixed Effects and are controlled for correlated variance of twin 
data. Abbreviations: BMI = Body Mass Index. CRP = C-Reactive Protein.  
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Table 2.5. Mixed model analyses for ED in relation to albumin, 
demographic factors, and other health variables. 
  ED 
Albumin 
B (SE) .75 (.34) 
t 2.2 
p .03 
Age 
B (SE) -.66 (.34) 
t -1.9 
p .06 
Hypertension 
B (SE) .97 (.67) 
t 1.4 
p .15 
High Cholesterol 
B (SE) -.23 (.65) 
t -.35 
p .73 
Depression 
B (SE) -.78 (.31) 
t -2.5 
p .01 
Pack Years 
B (SE) .11 (.32) 
t .34 
p .73 
CRP 
B (SE) .19 (.3) 
t .64 
p .53 
BMI 
B (SE) -.08 (.35) 
t -.21 
p .83 
Presented estimates and significance levels represent each parameter’s 
influence after all other terms have been entered into the equation. Results 
are Type III Fixed Effects and are controlled for correlated variance of twin 
data. Abbreviations: BMI = Body Mass Index. CRP = C-Reactive Protein. 
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Table 2.6. Mixed model analyses for ED in relation to AGR, demographic 
factors, and other health variables. 
  ED 
AGR 
B (SE) .87 (.33) 
t 2.6 
p .009 
Age 
B (SE) -.68 (.34) 
t -2.0 
p .047 
Hypertension 
B (SE) .65 (.6) 
t .98 
p .33 
High Cholesterol 
B (SE) -.34 (.64) 
t -.53 
p .6 
Depression 
B (SE) -.79 (.31) 
t -2.6 
p .01 
Pack Years 
B (SE) .05 (.32) 
t .16 
p .87 
CRP 
B (SE) -.24 (.3) 
t .79 
p .43 
BMI 
B (SE) -.1 (.34) 
t -.31 
p .76 
Presented estimates and significance levels represent each parameter’s 
influence after all other terms have been entered into the equation. Results 
are Type III Fixed Effects and are controlled for correlated variance of twin 
data. Abbreviations: AGR = Albumin/Globulin Ratio. BMI = Body Mass 
Index. CRP = C-Reactive Protein.	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  Table 2.7. Mixed model analyses for ED in relation to albumin and globulin, demographic factors, and other health variables. 
  ED 
Albumin 
B (SE) .64 (.34) 
t 1.9 
p .06 
Globulin 
B (SE) -.76 (.33) 
t -2.32 
p .02 
Hypertension 
B (SE) .77 (.67) 
t 1.14 
p .26 
High Cholesterol 
B (SE) -.19 (.65) 
t -.3 
p .77 
Depression 
B (SE) -.78 (.31) 
t -2.52 
p .012 
Pack Years 
B (SE) .06 (.32) 
t .19 
p .85 
CRP 
B (SE) .28 (.3) 
t .93 
p .35 
BMI 
B (SE) .00 (.35) 
t -.002 
p .998 
Age 
B (SE)	   -.65 (.34) 
t	   -1.91 
p	   .06 
Presented estimates and significance levels represent each parameter’s 
influence after all other terms have been entered into the equation. Results 
are Type III Fixed Effects and are controlled for correlated variance of twin 
data. Abbreviations: BMI = Body Mass Index. CRP = C-Reactive Protein. 
51	  
	  
 
 
 
 
 
 
 
 
 
CHAPTER III: 
ED Status and Cognitive Change Over Time: 
Implications for ED Assessment and Management 
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INTRODUCTION 
The graying of America with the Baby Boom generation has put late-life conditions in 
the spotlight. Erectile dysfunction (ED) is one such diagnosis that has garnered substantial 
attention. ED is an important condition to study in part because it is highly prevalent, with over 
320 million men worldwide estimated to suffer from it by 2025 (Aytac, McKinlay, & Krane, 
1999). Further, ED has been linked with quality of life (Litwin, Nied, & Dhanani, 1998), 
depression (Araujo, Durante, Feldman, Goldstein, & McKinlay, 1998), morbidity (Parazzini et 
al., 2000), and mortality (Araujo et al., 2009). It has long been known that one of the biggest risk 
factors for developing erectile difficulties is advancing age (McKinlay, 2000). Kinsey’s landmark 
studies in 1948 (Kinsey, 1948) documented that sexual dysfunction prevalence increased by 
decade, with 27% of 70-year-olds endorsing ED, 55% of 75-year-olds, and 75% of 89-year-olds. 
Other studies, like the Baltimore Longitudinal Study of Aging (Morley, 1986) and the 
Massachusetts Male Aging Study (Feldman, Goldstein, Hatzichristou, Krane, & McKinlay, 
1994), have replicated these trends. 
It is likely not be aging per se that is associated with sexual change, but specific 
correlates of aging: late-life diseases, changes in sex hormones, increased medication usage, 
declining physical strength, and partner availability/interest (Gades et al., 2009). One disease in 
particular – cardiovascular disease (CVD) – has been strongly linked to ED (Thompson et al., 
2005). It is now known that up to 80% of ED cases are due to physiological causes, with vascular 
disease the most common etiology (Jackson, Rosen, Kloner, & Kostis, 2006; Kendirci, Nowfar, 
& Hellstrom, 2005; Solomon, Man, & Jackson, 2003). 
Not only is ED frequently due to microvascular dysfunction, ED has proven to be a 
powerful predictor of future cardiovascular conditions. For example, ED frequently precedes the 
onset of angina by 2-3 years and adverse cardiovascular events by 3-5 years (Hodges, Kirby, 
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Solanki, O'Donnell, & Brodie, 2007; Montorsi et al., 2005). ED severity is related to the number 
and severity of CVD risk factors (Feldman et al., 1994) and they tend to co-occur, with up to 75% 
of coronary artery disease patients experiencing some degree of erectile difficulties (Feldman et 
al., 1994).  
It is believed that ED and CVD have shown such strong relationships because they share 
a similar pathogenic process. Specifically, the first stage of both disorders is represented by 
changes in the endothelium and smooth muscle. This dysfunction occurs even prior to plaque 
accumulation, and ultimately impairs the arteries and arterioles ability to dilate appropriately (for 
review, see Kirby, Jackson, & Simonsen, 2005). Currently, the prevailing theory connecting ED 
and CVD is the “artery size” hypothesis (Montorsi et al., 2005) though it should be noted that it 
has not received uniform support (Ponholzer et al., 2012). This theory posits that because 
different arteries throughout the body are of different sizes, the same level of vascular 
dysfunction will have a greater effect on the smallest arteries first. In this sense, the effects of 
penile artery atherosclerosis would manifest as ED, and should be apparent years before 
atherosclerosis becomes clinically evident in larger arteries of the body. Interestingly, penile 
arteries are more similar in size to cerebral small vessels, and because ED represents 
microvascular dysfunction, the condition may also signal the presence of cerebrovascular 
damage. 
Vascular dysfunction is important to study, in part because the degree of endothelial and 
smooth muscle damage has been linked with neuropsychological performance (Hoth et al., 2007; 
Moser et al., 2008). As the cardiovascular system ages, the development and progression of 
atherosclerosis provokes a cascade of pathological changes that culminate in vascular cognitive 
impairment (VCI). It now is widely established that individuals with CVD exhibit subtle 
cognitive deficits long before the onset of vascular dementia, and even prior to major cardiac 
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events like myocardial infarction or stroke (Gorelick et al., 2011). Deficits are most prominent in 
attention-executive-psychomotor speed domains (Haley et al., 2007) because frontosubcortical 
networks supporting these cognitive abilities are particularly vulnerable to ischemic damage 
(Pantoni & Garcia, 1997).  
Intriguingly, ED has typically been neglected in neuropsychological studies on aging. 
Our lab reported the first findings associating ED with neuropsychological performance (Moore 
et al., 2014). This cross-sectional study found that men with ED performed significantly worse on 
10 of the 11 cognitive domains. Differences were most pronounced in attention-executive-
psychomotor abilities. A second stage of analyses were conducted controlling for cardiovascular 
risk factors, demographic variables, and premorbid intellect. In these analyses, ED remained 
significantly associated with cognitive function in seven domains (processing speed, short-term 
memory, working memory, visuospatial memory, abstract reasoning, verbal fluency, and 
inhibition). Moreover, in these seven domains, ED was more strongly associated with current 
cognition than any other health variables analyzed, such as hypertension, high cholesterol, 
smoking and BMI.  
The cross-sectional nature of our study did not allow for us to unequivocally determine 
the temporal relationship between cognitive performance and ED symptoms. The large literature 
suggesting that impaired vascular function results in both ED and cognitive changes led us to 
examine longitudinal data from our sample in order to better characterize the nature of this 
association. 
The purpose of the present study is to determine if ED status moderates the rate of 
cognitive change across an average of five-year follow-up. Men with ED at baseline will be 
compared to their healthy peers on extent of change across a battery of cognitive domains.  Given 
that vascular dysfunction is most closely linked with attention-executive-psychomotor speed 
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domains (Haley et al., 2007), we hypothesize that men with ED will decline significantly more in 
these domains than men without ED. 
 
METHODS 
Participants 
The present study utilizes data from the Vietnam Era Twin Study of Aging (VETSA), a 
longitudinal study of cognition and aging beginning in midlife (Kremen et al., 2006). VETSA 
participants are from the Vietnam Era Twin Registry (VETR), a nationally representative sample 
of male–male twin pairs who served in the U.S. military sometime between 1965 and 1975. Most 
did not serve in combat. Detailed descriptions of the VETR and ascertainment methods have been 
previously reported (Kremen, Franz, & Lyons, 2013; Kremen et al., 2006). VETSA participants 
are similar to the general population of middle-aged American men in terms of socioeconomic 
status and health characteristics (Kremen et al., 2013). Participants traveled to laboratories at 
Boston University or the University of California, San Diego. The study was approved by local 
Institutional Review Boards.  Participants were, on average, 55 and 60 years of age at wave 1 
(VETSA 1) and wave 2 (VETSA 2), respectively. VETSA twins were randomly selected from a 
large prior study that attempted to enroll all available Registry twins (Tsuang, Bar, Harley, & 
Lyons, 2001). There were only two selection criteria to be in VETSA: twins had to be in their 50s 
at the time of recruitment and both twins in a pair had to be willing to participate in VETSA 1. Of 
the original 1237 participants, the final sample for the analyses reported here comprised 485 men 
with an average age of 55.3 years (SD=2.5; range: 51-60) at baseline.  
Given our interest in examining the relationship between cognition and ED as a 
subclinical harbinger of vascular disease, individuals were excluded if at baseline they were 
already diagnosed with cardiovascular disease (angina, diabetes, peripheral vascular disease, 
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myocardial infarction, heart failure, stroke, stent placement or heart surgery). Participants were 
also excluded if they were diagnosed with cancer, diabetes, multiple sclerosis, seizure disorder, 
substance abuse or dependence (at either baseline or follow-up). All of these conditions (and/or 
their medications) can affect cognition and/or erectile function, irrespective of underlying 
vascular burden.  History of any of these conditions was based on participants’ endorsement 
when asked if a doctor had ever told them that they had the condition.  
Perhaps counterintuitively, because we were interested in the relationship between 
cognition and the presence of ED, all participants who were already taking ED drugs (e.g. 
sildenafil, tadalafil) at baseline were excluded from analyses. This was a relatively small number 
of men (under two percent of our sample).  These drugs would alter their self-reported erectile 
function scores without altering their underlying vascular burden and could accordingly 
misrepresent that relationship. Further, we cannot unequivocally claim that men taking these 
medications would qualify for an ED diagnosis. There was a range of erectile function scores in 
this group, with many scoring in the normal range.  
Participants were also excluded if they had not attempted sex in the month prior to the 
VETSA 1 evaluation, given that is the timeframe that the erectile function measure is validated 
on. Lastly, men were excluded if they did not complete the erectile function measure. 
 
METHODS 
ERECTILE FUNCTION 
Erectile function was assessed with the International Index of Erectile Function-15 (IIEF-
15) (Rosen et al., 1997), a well-validated self-report questionnaire. The score represents the sum 
of six questions that address ED symptoms over the past four weeks.  Responses to each of the 
six items on the IIEF-15 are based on a rating scale from 1 to 5. They are summed to arrive at a 
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total score that can range from 6 to 30, with higher scores indicating better sexual health. ED is 
classified as mild (22-25), mild to moderate (17-21), moderate (11-16), and complete ED (6-10). 
Scores ranging from 26-30 suggest no clinically significant erectile difficulties. A binary 
classification of ED is defined as the presence of ED (scores ranging from 6-25) or absence of ED 
(scoring ranging from 25-30). For the purposes of the present study, we opted to utilize a binary 
classification of ED. We felt that a binary format may provide the most clinical utility and more 
readily transfers across ED measures, whereas the definition of severity groups may vary. 
Further, our cross-sectional analysis of ED and cognitive performance found similar relationships 
between ED and cognition, regardless of whether a binary, categorical, or continuous format was 
used.     
 
COGNITIVE OUTCOMES 
In the present study, we assessed the change in cognition across 13 neuropsychological 
domains. When a cognitive ability score incorporated more than one measure, individual 
measures were standardized (z-scored) and a composite score equal to the mean of the 
standardized scores was calculated. The 13 domains include: visual-spatial ability, episodic 
memory, short-term/working memory, processing speed, abstract reasoning, inhibition, verbal 
fluency, set-shifting, vocabulary, arithmetic word problems, mechanical reasoning/tool 
knowledge, visual-spatial organization, and general cognitive ability. 
Visual-spatial ability was based on the Hidden Figures Test and the Card Rotation test 
(Ekstrom, French, & Harman, 1976; Wechsler, 1997a).  
Episodic memory was assessed with the California Verbal Learning Test-Version 2 
(CVLT-2) (Delis, Kramer, Kaplan, & Ober, 2000) and the Logical Memory and Visual 
Reproductions subtests from the Wechsler Memory Scale-3 (Wechsler, 1997b)  CVLT scores 
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were the total score from Trials 1-5, short delay free recall and long delay free recall. Logical 
Memory scores were the immediate recall and delayed recall. Visual Reproduction scores were 
the immediate recall and delayed recall. 
Short-term/working memory was based on Reading Span Ascending and several WMS-3 
tests: Digit Span Forward raw score, Digit Span Backward raw score, Spatial Span Forward raw 
score, Spatial Span Backward raw score, Letter-Number Sequencing adjusted for Digit Span 
Forward. To isolate the working memory component of the Reading Span Ascending total score, 
the variable was adjusted for WRAT Reading raw score and Digit Span Forward raw score. 
Processing speed was derived from the Stroop word reading condition and Delis-Kaplan 
Executive Function System (D-KEFS)(Delis, 2001) Trail Making Test (Trails); both number 
sequencing trial and letter sequencing trial. 
Abstract reasoning ability was measured with scores from the WASI Matrix Reasoning 
subtest. 
Executive function.  Three aspects of executive function were addressed in our study. An 
inhibitory control measure was based on the Stroop Color Word Test interference condition score 
(Golden, 1978) adjusted for Stroop word reading. Verbal fluency was based on the total correct 
on the D-KEFS Letter (F,A,S) and Category (animals, boys’ names) Fluency tests.   Set-shifting 
was based on Trails number-letter switching condition adjusted for number sequencing and 
adjusted for letter sequencing, and the category-switching condition from D-KEFS Verbal 
Fluency (alternating between saying fruit words and furniture words) adjusted for Category 
(animal) Fluency scores.  These adjustments were performed in order to isolate the contribution 
of cognitive inhibition or set-shifting abilities from processing speed. 
The final instrument utilized was a general cognitive ability measure. This was the 
Armed Forces Qualification Test (AFQT) (Bayroff & Anderson, 1963), which is a 100-item 
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multiple-choice test that is highly correlated with Wechsler IQ and other general cognitive ability 
measures (Lyons et al., 2009; McGrevy, Knouse, & Thompson, 1974). Questions on the AFQT 
are equally divided into four domains of (1) vocabulary, (2) arithmetic word problems, (3) 
mechanical reasoning/tool knowledge (4) visual-spatial organization. Domain scores of these 
four categories were analyzed, in addition to the total score representing general cognitive ability. 
Mean AFQT percentile score at VETSA 1 was 64, corresponding to a WAIS score of 
approximately 105.  
 
HEALTH AND DEMOGRAPHIC COVARIATES 
Participants were also assessed for a variety of measures that could be related to cognitive 
function, including age, body mass index (BMI), smoking, high cholesterol, hypertension, 
depressive symptoms, and cognitive ability from early adulthood. Hypertension was ascribed to 
participants if they endorsed that a physician had given them this diagnosis, or had blood pressure 
on the day of testing above 140 systolic or 90 diastolic. High cholesterol was ascribed to 
participants who or endorsed that a physician had diagnosed them as having 
hypercholesterolemia, or if their blood draw on the day of testing had LDL, HDL, and/or total 
cholesterol levels conventionally considered to be high risk (LDL: > 160 mg/dL; HDL: <40 
mg/dL; Total cholesterol: >240 mg/dL). Depressive symptoms were measured by the Center for 
Epidemiologic Studies-Depression Scale (CES-D) (Radloff, 1977).  
 Because certain questions were removed from our baseline evaluation to our follow-up, 
our assessment of smoking changed. At our baseline assessment (VETSA 1), men were queried 
about their smoking history, including when they began smoking and how many cigarettes they 
were smoking per day. From that, a pack years variable (packs of cigarettes smoked per day x 
years smoked) was calculated, and we were able to determine how many pack years each 
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participant had at VETSA 1. Participants were not queried about their current smoking frequency 
at our follow-up assessment (VETSA 2). To estimate pack years at VETSA 2, we made the 
assumption that all men smoking at VETSA 1 would still be smoking at VETSA 2, and all men 
who had quit smoking by VETSA 1 would still be abstaining at VETSA 2. For men who 
endorsed being current smokers at VETSA 1, we calculated a “pack years rate” (pack years at 
VETSA 1 / number of years smoked) and multiplied this rate by the numbers of year they had 
smoked, now extending through VETSA 2. For example, if a man had 30 pack years (e.g., 15 
years of smoking 2 packs per day) at VETSA 1 and endorsed being a current smoker, 5 years 
later when he came in for his VETSA 2 evaluation, his new estimated pack years would be 40 (30 
pack years / 15 years of smoking = a rate of 2 pack years/ year; 2 pack years/ year * 20 years of 
smoking [15 years through VETSA 1 plus 5 years to VETSA 2). If a man had stopped smoking 
by VETSA 1, his pack years variable at VETSA 2 was equal to his pack years value at the 
baseline evaluation. In other words, if a participant had 30 pack years at VETSA 1 but quit 
smoking prior to his VETSA 1 assessment, it was presumed that he had acquired no more pack 
years and his estimated pack years at VETSA 2 would remain as 30. Participants who endorsed 
never smoking in their lifetime were given a pack years of zero.  
 Groups were compared on early adulthood cognitive ability as measured by the AFQT 
(described above)(Bayroff AG, 1963). VETSA affords a unique opportunity to utilize premorbid 
cognitive ability scores since all participants were administered the AFQT at around age 20. The 
AFQT has high reliability, demonstrating a test-retest correlation of .74 over the 35-year interval 
between average age 20 and the VETSA study (Lyons et al., 2009). 
 In comparison to our cross-sectional study on ED and cognition (Moore et al., 2014), the 
present study differs in two important ways. First, the cognitive domains have slightly changed, 
as not all tests done at VETSA 1 were done at VETSA 2. For example, the Vocabulary domain 
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included at VETSA 1 was composed of the WAIS-IV Vocabulary subtest not administered in 
VETSA 2, and consequently this domain was modified. Other domains are also slightly 
abbreviated compared to the previous publication, and a one-to-one comparison of test findings is 
not possible. The second important difference between the present findings and our previous 
publication concerns our sample population. For men to be included in the present study, not only 
did they have to be free from CVD at baseline, they also needed to be free from cancer at baseline 
and follow-up (as this was later decided to be an important exclusion criterion for reasons 
addressed above), and they needed to have complete cognitive and ED data from both VETSA 1 
and VETSA 2. 
 
Statistical Analysis 
 The analyses were non-twin analyses, i.e., individuals, not twin pairs, were the unit of 
analysis. All analyses adjusted for the clustering of twins within pairs with mixed modeling in 
SPSS 19.  We began by testing for mean differences in demographic and health variables between 
ED and non-ED (N-ED) groups to better characterize the sample.  
 Our next two stages of analyses employed mixed models to determine if men with ED at 
baseline performed significantly poorer than men without ED across the 13 cognitive domains. 
The first stage of analyses looks at whether ED is cross-sectionally associated with cognitive 
performance in VETSA 1, and the second stage of analyses looks at whether baseline ED predicts 
cognitive performance at VETSA 2.  
Our third stage of analysis employed mixed modeling to determine whether men with ED 
change at a significantly different rate on cognitive measures from VETSA 1 to VETSA 2, as 
compared to men without ED. In these analyses, the dependent variable of interest will be the 
calculated difference score (Time 2 – Time 1), rather than Time 2 covaried for Time 1. When 
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significant differences exist at baseline, this latter method has been shown to be too liberal, 
leading to increased likelihood of type 1 errors.  This statistical procedure is in line with 
recommendations put forth by Van Breuekelen (2006). 
 In this third stage of analyses, we compared ED and N-ED groups on the change 
scores from the 13 cognitive domains; each cognitive domain was run separately. Cognitive 
domains for which ED was a significant predictor were then subject to a second round of analysis 
whereby age, health factors, and premorbid cognitive ability were included as covariates. 
Presented estimates and significance levels represent each parameter’s influence after all other 
terms have been entered into the equation (Type III fixed effects).  
 To correct for multiple analyses being run, we employed the two-stage sharpened 
False Discovery Rate (FDR) control in each of the three stages of mixed models (Benjamini, 
Krieger, and Yekutieli, 2006). The sharpened FDR is determined by computing ai by ranking the 
p-value of each of the n tests from smallest (p1) to largest (pn) and multiplying each p-value by n 
divided by the rank (i) of that p-value (ai=pi⁎n/i). Tests in which a<.05 remain significant, while 
those with a>.05 are deemed false discoveries.  
 It is anticipated that many men will not show substantial change across domains 
from baseline to follow-up. A classic problem with group analyses is that the group’s average 
score contains participants who declined, who improved, and who remained stable. Alas, this 
final stage of analyses will examine whether ED confers greater risk for being a “decliner” – one 
whose change scores were greater than 1.5 standard deviations from the mean. This magnitude of 
difference was selected because exceeding 1.5 standard deviations is conventionally viewed as 
significantly outside of the normal range. Further, it is typical for individuals with mild cognitive 
impairment (MCI) to score 1.5 standard deviation below the mean of their peer group on 
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cognitive tests, and, in fact, many studies use this deficit cut-off as one of the selection criteria for 
MCI (Petersen, 1999). Odds ratios were used to analyze degree of risk. Statistical significance 
was defined by 95% confidence intervals not crossing unity. 
   
RESULTS 
After applying exclusionary criteria, 491 participants remained. In total, 746 men were 
excluded for the following reasons: taking ED medications (n=22), no sexual activity over the 
past month (n=293) myocardial infarction (n=78) angina (n=40), heart failure (n=11), peripheral 
vascular disease (n=15), seizures (n=16), multiple sclerosis (n=5), stroke (n=23), alcohol abuse 
(n=42), substance use disorder (n=16), schizophrenia (n=3), heart surgery (n=89), cancer at 
baseline (n=20), cancer at follow-up (n=34), or did not complete the erectile function 
questionnaire and/or cognitive measures (n=39). Demographic and health comparisons are shown 
in Table 3.1.  
Included participants did not differ from excluded participants on age, education, or 
premorbid cognitive ability, but they were less depressed, smoked less, had lower BMI, less 
hypertension, and less hypercholesterolemia. Additionally, there was a higher frequency of 
diabetes, angina, heart failure, heart attack, stroke, heart surgery, and stent placement in the 
excluded participants, given that these were exclusionary criteria. Of the included sample, 27.3% 
(n=134) endorsed some degree of ED (13.2% mild [n=65]), 6.3% mild-to-moderate [n=31], 4.5% 
moderate [n=22], and 3.3% severe [n=16]). All ED sub-groups were collapsed to form the final 
ED group. For the remaining analyses, ED classifications were collapsed into an ED group and a 
non-ED group (referred to as N-ED).  
Men with ED had significantly higher BMI at baseline (p=.01) and follow-up (p=.03), 
more depressive symptoms at baseline (p=.001) and follow-up (p=.02). There was a trend-level 
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finding for men with ED to have fewer years of education (p=.05). No significant differences 
were found between groups with regard to age, premorbid intelligence, smoking (at baseline or 
follow-up), high cholesterol (at baseline or follow-up), or hypertension (at baseline or follow-up). 
Descriptive statistics can be found in Table 3.2. 
In the first series of mixed models, which looked at whether ED was associated with 
diminished cognitive functioning, the ED group performed significantly worse on 7 of the 13 
cognitive domains and had trend-level findings in two others in the same direction. ED was 
associated with significantly poorer verbal fluency, episodic memory, short-term/working 
memory, set-shifting, processing speed, abstract reasoning, and arithmetic (see Table 3.3). Based 
on the two-stage sharpened False Discovery Rate method, all findings remained significant. The 
trend-level results were found on the AFQT (the measure of general intellect), and on the 
visuospatial organization subdomain of the AFQT. 
The second series of mixed models looked at whether ED at baseline was associated with 
diminished cognitive functioning approximately five years later. As seen in Table 3.4, ED was 
associated with significantly poorer cognitive performance in 10 of the 13 cognitive domains: 
verbal fluency, episodic memory, short term/working memory, set-shifting, processing speed, 
general intellect (AFQT), visuospatial reasoning (AFQT – Boxes), and arithmetic abilities. Based 
on the FDR adjustment, all findings remained significant. There was a trend-level finding for a 
significant difference in abstract reasoning in the same direction.  
The third series of mixed models examined whether ED at baseline predicted a steeper 
cognitive decline from baseline to follow-up. As seen in Table 3.5, men with ED at baseline 
declined significantly faster on set-shifting abilities and tools/mechanical relations (AFQT – 
Tools). Findings remained significant when controlling for age, BMI, depression, hypertension, 
high cholesterol, and premorbid cognitive function. In fact, ED was the single significant 
65	  
	  
predictor of change in tools/mechanical knowledge [β=-5.2, F(1, 470.15)=7.2, p=.007]. ED and 
hypertension revealed to be the only significant predictors of set-shifting decline, with ED 
appearing to be a more powerful predictor [ED: β=-.2, F(1, 466)=6.8, p=.009; Hypertension: β=-
.16, F(1, 458.5)=.5.2, p=.02]. When adjusting for multiple comparisons, the findings remained 
significant. There was a trend-level finding for a differential decline in general intellect as well 
(AFQT total score: p=.06).  
As discussed above, the set-shifting latent variable was derived by combining 
performance on two instruments: DKEFS Trails 4 (a graphomotor set-shifting test) and DKEFS 
Verbal Fluency Category Switching Accuracy (a verbal set-shifting test). Post-hoc analyses 
revealed that men with ED demonstrated a significantly greater decline on both tests individually 
(Trails 4: F[1, 485]=6.4, p=.01; Category Switching: F[1, 488]=3.8, p=.05). In other words, the 
significant difference between the ED and N-ED groups in the set-shifting domain was not driven 
by results from one test, but rather both tests with a set-shifting component produced similar 
findings.  
Across many domains the average change scores between men with and without ED were 
not significantly different from each other. A final stage of analysis was conducted to determine if 
men with ED were more likely to be “decliners” – in other words, those who showed significant 
cognitive decline (>1.5 STD of the change score) in the domains in which the mean scores 
suggested no significant difference between groups. Odds ratio estimates and 95% confidence 
intervals for each of the variables are presented in Table 3.6. The odds ratio of ED compared with 
N-ED subjects was 2.37 for being a “decliner” in verbal fluency (95% confidence interval, 1.03 – 
5.42) and 2.55 for being a “decliner” in AFQT Vocabulary (95% confidence interval, 1.26 – 
5.17). When controlling for age, BMI, depression, hypertension, high cholesterol, and premorbid 
cognitive function in a mixed model, findings remained significant. In fact, ED was the only 
66	  
	  
significant predictor of being a decliner in verbal fluency [F(1, 472)=6.6, p=.01]. ED and lower 
premorbid intelligence (AFQT) were the only predictors of decline in vocabulary knowledge 
[ED: F(1, 472)=7.8, p=.005; AFQT: F(1, 472)=10.6, p=.001]. 
 
 
DISCUSSION 
Over the past few decades, a vast literature has burgeoned documenting ED as a powerful 
cardiovascular risk factor. Although the biological mechanism linking ED with CVD remains 
unclear, ED is an intriguing variable to study because it affords researchers an opportunity to 
identify men at greatest vascular risk before a cardiovascular event occurs. Our initial study 
(Moore et al., 2014) found that ED was strongly associated with poorer cognitive performance 
across a battery of cognitive tests. ED was most strongly related to attention-executive-
psychomotor speed tasks – which is consistent with the cognitive profile found in vascular 
disease. The present analyses report a follow-up of that study, determining if ED is associated 
with a change in cognitive function over time.  
The results from the present study reveal that men with ED had significantly poorer 
verbal fluency, episodic memory, short-term/working memory, set-shifting, processing speed, 
abstract reasoning, and arithmetic at baseline. ED was significantly associated with poorer verbal 
fluency, episodic memory, short term/working memory, set-shifting, processing speed, abstract 
reasoning, general intellect, visuospatial reasoning and arithmetic almost six years later (on 
average).  
When controlling for baseline performance (i.e., looking at change scores from baseline 
to follow-up), the findings from the present study suggest that men with ED are, on average, 
declining at a significantly greater rate on tests of set-shifting and tools/mechanical knowledge, as 
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compared to their healthy peers. Post-hoc analyses revealed that both set-shifting tests (one 
graphomotor and one verbal) consistently found that men with ED declined at a significantly 
greater rate than men without ED. With two distinct set-shifting tasks producing similar results, 
this suggests the significant difference between the groups is not a Type 1 error, nor is it limited 
to graphomotor or verbally mediated tests. 
Set-shifting is a higher order executive function, and it is well documented that men with 
CVD have deficits in this domain (Jokinen, Kalska, mMantyla, Pohjasvaara et al., 2006), as this 
domain is sensitive to frontosubcortical damage. Our findings suggest that ED is predictive of 
decline in this executive function, which is consistent with the conceptualization of ED as a 
precursor to overt CVD. 
The decline in tools and mechanical knowledge is intriguing and was not part of our 
original hypothesis. However, the literature suggests that testosterone in older men is associated 
with visuospatial ability (Janowsky, Oviatt, & Orwoll, 1994; Moffat et al., 2002). This is relevant 
because up to 40% of aging men with ED may have below normal levels of testosterone (Greco, 
Spera, & Aversa, 2006). Low testosterone is not only associated with ED, it also enhances 
cardiovascular risk. Unfortunately information on testosterone levels was not available for the 
entirety of this sample, so it is unclear if testosterone levels are mediating the relationship 
between ED and decline on the mechanical/tool knowledge.  
With regard to changes in other cognitive domains, the group means were similar 
between men with and without ED. In fact, across many measures, the total sample means did not 
decline notably from the baseline evaluation. This may not be particularly surprising for several 
reasons. First, our sample consists of relatively young men who are in good health and may not 
be expected to exhibit significant cognitive change in their late 50s in the absence of deleterious 
medical conditions. Second, practice effects have been found five years later (Rönnlund, Nyberg, 
68	  
	  
Bäckman, & Nilsson, 2005), so even if pure cognitive change did occur, it may be counteracted 
by inflated performance due to practice benefits. Despite this finding of minimal cognitive change 
in the group average, it is expected that on any given measure, some men will have improved 
across time, others will have remained stable, and some will have declined. Identifying the 
“decliners” in each domain is helpful because it allows us to determine what factors are 
associated with risk for abnormal cognitive change. 
When looking at men whose cognitive decline exceeded the normal range, our analyses 
revealed that men with ED were at approximately 2.5 times greater risk of falling into this 
“decliner” category on verbal fluency and vocabulary knowledge measures. These findings are 
partially consistent with our hypothesis that men with ED would show greatest declines in the 
attention-executive-psychomotor speed domains, as verbal fluency tasks involve speed and 
executive functioning. Verbal fluency is frequently found to be diminished in vascular disease 
(Tierney et al., 2001) and has been shown to be associated with endogenous testosterone levels as 
well (Wolf & Kirschbaum, 2002), which are frequently diminished in ED. 
The finding regarding ED as a predictor of who declined on the vocabulary test is not as 
easily explained. Vocabulary knowledge, in general, is believed to be a crystallized cognitive 
ability (i.e., a domain least sensitive to change as we age). For this reason, single-word reading 
tests and vocabulary definition tests are frequently used in neuropsychological batteries as indices 
of premorbid cognitive ability. Given this, we did not hypothesize that men with ED would be 
more prone to change on this test. However, other studies have also documented an association 
between cardiovascular risk and vocabulary decline. Kaffashian and colleagues (2013) found that 
cardiovascular risk factors significantly predicted a decline in vocabulary over 10 years. Gimeno 
et al. (2011) found that elevated inflammatory biomarkers (which are a risk factor for ED) were 
associated with declines in vocabulary over time as well. Other studies have documented 
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significant declines in vocabulary in patients with vascular dementia (Gunstad et al., 2005; 
Nyenhuis, Gorelick, Freels, & Garron, 2002). Evidence suggests that inflammation differentially 
affects diverse aspects of cognition, including verbal crystallized intelligence, and has differing 
impacts at different stages of neurodegeneration (Krabbe et al., 2009). As we know that ED is 
associated with elevated inflammation (Vlachopoulos et al., 2006), it is possible that their high 
inflammatory state contributed to the significant vocabulary decline. It is also possible that the 
decline in vocabulary that we observed may simply be a statistical artifact. Further research is 
needed on the topic to fully understand our findings. 
In contrast to our original study examining the relationship between ED and cognitive 
function (Moore et al., 2014), the present study allowed us to examine whether ED is associated 
with cognitive function across time. Cross-sectionally, ED was associated with poorer cognitive 
performance on 7 of 13 neuropsychological domains. Men with ED at baseline had significantly 
poorer cognitive performance in 10 out of the 13 neuropsychological domains at follow-up (on 
average 6 years later). By evaluating these statistics, it appears that ED’s relationship with 
cognition strengthens over time. However, when looking at the change scores, baseline ED 
appears to only significantly predict cognitive change in aspects of executive function (set-
shifting, verbal fluency), mechanical knowledge, and vocabulary. ED is not predictive of a 
change in processing speed, short-term/working memory, abstract reasoning, visuospatial 
reasoning, inhibition, episodic memory, arithmetic, or general intelligence. There are several 
possible explanations for this finding. First, our sample consists of young, non-patient middle-
aged men who have not yet experienced substantial cognitive decline. In fact, across many tests a 
substantial proportion of men improved rather than declined across time. Though men with ED 
consistently demonstrated significantly poorer cognitive functioning across a comprehensive 
battery of tests at both time points, the magnitude of change may be too little to detect significant 
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differences between groups. It is possible that ED may be more predictive of change across time 
in an older sample at greater risk for cognitive change. Another plausible explanation is that the 
direction of causality is reversed, whereby men with lower premorbid intelligence are more prone 
to lead an unhealthy lifestyle that results in increased vascular risk factors and are ultimately at 
more risk to develop ED. That is, the significant cognitive differences between groups may reflect 
premorbid cognitive functioning that predates the development of ED. An argument against this 
direction of causality is that men with ED performed similarly to men without ED on a measure 
of general intellect nearly 40 years ago. Although our results revealed a trend-level finding of ED 
associated with fewer years of education, it is widely agreed that years of education is not ideal as 
a premorbid estimate of intelligence (Vanderploeg & Schinka, 2003), in part because it suffers 
from a severely restricted range, and it does not capture differences in quality of education.  
The importance of these findings is three-fold. First, this is the first study to demonstrate 
that ED status predicts cognitive performance five years later. When adjusting for baseline 
performance, ED was associated with significantly greater decline in some aspects of executive 
dysfunction and mechanical knowledge. When exclusively looking at men who declined 
significantly from baseline to follow-up, men with ED were at greater risk than their healthy 
peers to have declined in verbal fluency and vocabulary. The findings from the present study and 
those from our previously published analyses (Moore et al., in press) suggest that more research 
on ED within the realm of neuropsychological studies is warranted. In particular, studies 
measuring ED with direct physiological assessment (e.g. via venous occlusion plethysmography) 
would be useful, both to replicate the findings between erectile function and cognition, but also to 
tease apart which stage of vascular dysfunction (for example, smooth muscle dysfunction versus 
endothelial dysfunction) is implicated in the relationship. 
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Second, our findings are notable because we demonstrated a relationship between ED and 
cognitive performance in a relatively young, community-dwelling cohort of middle-aged men 
who have not yet experienced substantial cognitive decline. Detecting subtle changes, like the 
ones documented in the present study, are important because it is now known that cognitive 
performance is significantly (and linearly) associated with vascular integrity (Moser et al., 2006). 
This is in sharp contrast to much of the original work on cognitive performance and vascular 
disease, which exclusively emphasized the stepwise pattern of cognitive change that occurs in the 
context of cerebrovascular infarctions (Erkinjuntti, 2002). Identifying those at risk for vascular 
cognitive impairment as early as possible is beneficial from both clinical and research 
perspectives. Clinically, understanding that ED is a marker for elevated risk for cognitive decline 
is important because it may indicate that a patient should undergo neuropsychological evaluation 
to establish a baseline, or suggest that a patient may benefit from medications or lifestyle 
interventions targeted at slowing or reversing the atherosclerotic process. From a research 
perspective, understanding that ED is linked to cognitive function is useful because it may be 
used as an inclusionary criterion (or exclusionary criterion, depending on the scientific question) 
on studies targeting early stages of cognitive change.  
Third, our findings underscore the importance of recognizing (and conveying) the fact 
that ED is a systemic disorder. Though the medical literature is replete with studies linking ED to 
increased cardiovascular morbidity and mortality, research also suggests that the majority of men 
with ED do not notify their healthcare providers (Shabsigh, Perelman, Laumann, & Lockhart, 
2004). Increased emphasis should be placed on educating men about the serious correlates of ED: 
morbidity (Thompson et al., 2005), mortality (Gazzaruso et al., 2008), cognitive decline, and 
decreased quality of life (De Berardis et al., 2002).  
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Strengths and limitations of the study should be noted. It is likely that some ED cases had 
non-vascular etiologies (e.g., trauma, medication side effects, partner unavailability, stress). 
However, the likelihood of this representing a substantial proportion of our cases is quite low. It 
is believed that up to 80% of ED can be attributed to organic causes, with vascular dysfunction 
most prominent (Virag, Bouilly, & Frydman, 1985). Moreover, the Princeton III guidelines 
suggest that a man with ED and no cardiac symptoms should be considered to have vascular 
disease until vascular disease is ruled out (Nehra, et al., 2012). It is also known that many men 
with ED remit over time (Travison et al., 2007), so some men with ED at baseline may have 
recovered by follow-up. In any case, this would likely serve to blunt our findings rather than 
enhance them. It is also possible that correlates of ED (e.g. low SES, physical inactivity, 
psychological stress) account for its relationship with cognition, independent of vascular health. 
Unfortunately, direct assessment of vascular function was beyond the scope of the present study, 
but future research is warranted to better elucidate these findings. 
We assessed ED with a self-report measure rather than physiological assessment.  
However, the IIEF-15 is considered one of the gold-standard self-report assessments of ED and it 
has been well-validated. The IIEF-15 does ask only about the past four weeks of sexual activity.  
It is possible that a more expansive window of time could be useful because it would allow for 
inclusion of more participants, although that could be offset by greater reliance on more distant 
recall.  
Relatedly, some men who are not attempting sex are doing so because they have erectile 
difficulties. Including them in the analyses may have increased generalizability of the sample. 
However, there are several valid reasons why men may not attempt sex, many of which have 
nothing to do with erectile function (e.g. no partner availability/ no partner interest, physical 
disability of self or partner, etc.). For some of our men, their last sexual attempts ranged from 
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months to years ago. If we included these men in our analyses, we would be comparing their past 
erectile function to their current cognition, thereby changing the nature of the findings. Future 
studies could obviate this issue by utilizing direct physiological assessment to diagnose ED, 
rather than relying on self-report measures. Because ED assessment was not the primary outcome 
of the larger VETSA study, direct vascular assessment of ED was beyond the scope of this study. 
Another limitation concerns the fact that our participants’ medical histories were 
determined by self-report. It is possible that some of our participants had been previously 
diagnosed with one of our exclusionary criteria (e.g. angina) and failed to recall this during the 
medical interview. Similarly, some of our participants may currently be suffering from one of our 
exclusionary conditions that may not yet be diagnosed. Although this could result in the improper 
inclusion of some participants in the present analyses, the likelihood of this representing a 
meaningful portion of our sample is quite low. Indeed, Baumeister and colleagues (2010) have 
shown that self-report for medical history is highly reliable and valid.  
It might be considered a limitation that 58% of our sample was excluded.  Despite our 
exclusionary criteria, we were still left with a relatively large sample, and it was necessary to 
exclude many conditions to confidently conclude that it was ED—rather than other factors—that 
was associated with cognitive decline.  In one study of men ages 50-80 years, ED was associated 
with increased cardiovascular risk, but it was not an age-independent predictor (Ponholzer, 
Gutjahr, Temml, & Madersbacher, 2010). With a 30-year age range, the effects of age may have 
been substantial enough to overshadow ED effects.  In contrast, our age-homogeneous sample 
enhances the ability to detect individual differences unrelated to age differences. Therefore, the 
importance of ED is supported and strengthened by the fact that it remained a significant factor 
even with stringent exclusion criteria in a relatively young, age-homogeneous sample. However, 
given these exclusions, our findings are only relevant in men without cardiovascular disease. 
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While it will be important to determine whether ED is indicative of compromised cognition in 
clinical populations, that was beyond the scope of this initial study. 
Relatedly, it is possible that the observed relationships between cognition and 
conventional cardiovascular or other risk factors would be more prominent had we not excluded 
individuals with cardiovascular disease (as these individuals would be most likely to exhibit 
hypertension, high cholesterol, increased smoking, etc.). That said, it is also plausible that 
individuals with cardiovascular diseases would also exhibit more cases of ED, and thus our 
findings may be strengthened. Future studies are warranted to extend these findings to clinical 
populations. Nevertheless, the findings presented in this study are clinically relevant because they 
inform clinicians that ED can negatively impact cognitive function even in men free of 
cardiovascular disease.  
CVD can lead to vascular cognitive impairment and dementia, and early identification of 
at-risk individuals is critical to preserve heart and brain health. Though the literature is replete 
with studies documenting the importance of ED as a prognosticator for CVD, ED has been left 
out of studies examining its relationship to cognitive functioning. As the prevalence of ED 
continues to rise – with over 320 million predicted to have ED in 2025 (Aytac, et al., 1999) – it is 
important to better characterize the disorder in terms of cognitive correlates and medical 
comorbidities. Dementia prevalence is predicted to double every 20 years (Prince et al., 2013). 
Identifying early indicators of cognitive impairment is a priority for healthcare professionals as it 
allows opportunity for intervention, saving both lives and money, and preserving quality of life.  
While much of research emphasis has been placed on early treatments for Alzheimer’s 
dementia, vascular disease is believed to account for approximately 25-30% of all dementia cases 
(O’Brien et al., 2006). The framework for understanding vascular dementia has evolved 
considerably. The original understanding of vascular cognitive impairment was based on the 
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stroke and multi-infarct stepwise model (O’Brien et al., 2006), but now it is well recognized that 
vascular cognitive impairment can be gradual in nature, as occurs in small-vessel disease 
(Pantoni, 2010). In fact, the primary vascular mechanism in subcortical ischemic vascular disease 
is small-vessel disease (Kalaria, 2012). Because penile arteries are similar in size to cerebral 
arteries, dysfunction in penile arteries may signal early stages of cerebrovascular degradation.  
There is a growing appreciation for the relationship between vascular dementia and 
Alzheimer’s dementia. In this regard, gaining a better understanding of vascular disease risk 
factors is important because, in addition to directly leading to vascular dementia, many of these 
factors are significantly associated with increased Alzheimer’s risk as well [e.g. hypertension and 
high cholesterol (Kivipelto et al., 2001), diabetes (Messier, Awad, & Gagnon, 2004), smoking 
(Ott et al., 1998), obesity (Profenno, Porsteinsson, & Faraone, 2010)]. The impact of vascular and 
AD pathologies also appear to be additive (Jick et al., 2000), and the majority of dementia cases 
demonstrate both vascular and Alzheimer’s disease.  
In sum, results from this study demonstrate that ED is significantly associated with 
decline in aspects of executive functioning and tool/mechanical knowledge over time in a 
community-dwelling midlife sample of men with no diagnosed CVD. Because ED is a precursor 
to overt CVD, our results suggest that individuals at greater risk of developing CVD are already 
demonstrating significant cognitive differences from those at lesser risk. Future research is 
warranted to replicate and extend these findings. In particular, studies that measure erectile 
function via direct physiological assessment will be useful to determine if cognitive performance 
is associated with physiological indices of ED (e.g. Doppler radar of blood flow), or better 
accounted for by comorbidities of the condition (e.g. depression). 	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Table 3.1.  Group differences between included participants and excluded participants in 
the present analyses. 
 Included  
(n=491) 
Excluded  
(n=746) 
   
 M (SE) 
M 
(SE) F df P 
Age, Baseline 55.43 (.1) 55.43 (.1) .01 499.6 .9 
Education, years 13.8 (.1) 13.9 (.1) 1.03 939.9 .31 
AFQT .34 (.03) .35 (.03) .19 868.3 .66 
Depression 7.1 (.4) 9.6 (.37) 25.6 1013.8 <.001 
Smoking (Pack years) 17.2 (1.1) 21.9 (1.05)  10.9  969.8 .001 
BMI 28.9 30.0 12.8 933.3 <.001 
Hypertension, % 51.5 65.8 25.1 1013.73 <.001 
High Cholesterol, % 25.0 38.1 21.1 1047.8 <.001 
Angina 0 13.7 76.4 1049.8 <.001 
Myocardial Infarctiona, 
% 0 13.2 20.2 1051 <.001 
Strokea, % 0 3.9 4.2 1051 .04 
Diabetesa, % 0 22.5 133.7 1038.7 <.001 
Peripheral Vascular 
Diseasea, % 0 2.5 .72 531.7 .4 
Heart Failurea, % 0 1.9 8.4 1024.2 .004 
Heart Surgerya, % 0 15.1 14.4 1044.9 <.001 
Stent Placementa, % 0 7.8 81.5 1032.7 <.001 
Note:  All analyses control for the clustering of twins within pairs.  AFQT serves as index 
of premorbid cognitive ability from age 20. Abbreviations: AFQT = Armed Forces 
Qualification Test. BMI = Body mass index.  Df = degrees of freedom. aExclusionary 
criteria.  
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Table 3.2. Group differences on demographics and cardiovascular risk factors between the 
ED and N-ED groups.  
 N-ED  (n=357) 
ED  
(n=134) 
   
 M  (SE) 
M  
(SE) F p df 
Age, Baseline 55.4 (.13) 55.3 (.14) 2.49 .12 124.2 
Age, Follow-
Up 61.1 (.13) 61.1 (.14) .34 .56 130.4 
Follow-up 
Time 5.7 (.04) 5.7 (.05) .15 .7 187.0 
Education 
(years) 14.0 (.12) 13.6 (.18) 3.9 .05 440.9 
AFQT .36 (.04) .32 (.05) .49 .49 437.4 
BMI, Baseline 28.6 (.25) 29.6 (.36) 6.3 .01 412.6 
BMI, Follow-
Up 29.2 (.29) 30.2 (.42) 4.7 .03 403.4 
Depression, 
Baseline 6.38 (.4) 8.7 (.6) 11.9 .001 483.0 
Depression, 
Follow-Up 6.15 (.4) 7.93 (.66) 5.5 .02 473.6 
Smoking, 
Baseline (Pack 
Years) 
16.3 (1.3) 19.7 (1.9) 2.62  .11 418.3 
Smoking , 
Follow-Up 
(Pack Years) 
 20.3 (1.5) 24.0 (2.2) 2.16 .14 417.83 
High 
Cholesterol, 
Baseline (%) 
22.7 27.7 1.37 .24 487.7 
High Cho, 
Follow-Up (%) 53.2 54.5 .05 .8 478.7 
Hypertension, 
Baseline (%) 52.2 52.5 .003 .95 472.6 
Hypertension, 
Follow-Up (%) 63.9 59.2 .96 .33 485.9 
Note: Results are Type III Fixed Effects and are controlled for correlated variance of twin 
data. AFQT serves as index of premorbid cognitive ability from age 20. 
Abbreviations: N-ED = Non-ED group. AFQT = Armed Forces Qualification Test. BMI = 
body mass index. 
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Table 3.3. Cognitive Performance in ED vs. N-ED Participants at baseline (VETSA 
Wave 1). 
Cognitive Ability N-ED  (n=357) 
ED  
(n=134) F p df 
Verbal Fluencyb .1 (.05) .21 (.07) 13.3 <.001 467.3 
Visuospatial 
Abilityb .07 (.06) -.03 (.08) 1.3 .25 418.6 
Episodic 
Memoryb .09 (.04) -.11(..06) 8.7 .003 476.2 
STMb .07 (.03) -.12 (.05) 12.7 <.001 433.9 
Set-Shiftingb  .04 (.04) -.11 (.07) 4.1 .04 471.7 
Inhibition 47.78 46.9 1.61 .2 470.4 
Processing 
Speedab .15 (.04) -.10 (.05) 16.0 <.001 454.8 
Abstract 
Reasoning 24.0 (.31) 22.5 (.48) 7.6 .006 459.2 
AFQT 66.2 (1.1) 62.6 (1.7) 3.7 .06 433.4 
AFQT – Boxes 51.1 (1.6) 46.0 (2.4) 3.5 .06 472.03 
AFQT – Tools 66.5 (1.4) 63.5 (2.0) 1.8 .18 440.4 
AFQT – 
Arithmetic 66.0 (1.5) 60.9 (2.18) 4.3 .04 452.5 
AFQT - 
Vocabulary 84.3 (.9) 83.1 (1.5) .45 .5 486.8 
Results are Type III Fixed Effects and are controlled for correlated variance of twin data. All 
cognitive scores were centered with a mean-0, and standard deviation -1.  
Abbreviation: STM= Short-term/working memory; AFQT= Armed Forces Qualification 
Test.  
a Time scores were reverse-coded so that higher scores indicate better performance on all 
measures.  
bMultiple tests were combined to create this variable, and the mean was standardized (z-
scored). 
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Table 3.4. Cognitive Performance in ED vs. N-ED Participants at Follow-Up 
(VETSA Wave 2). 
 N-ED  (n=357) 
ED  
(n=134)   
 
Cognitive Ability M (SE) 
M 
(SE) F p df 
Verbal Fluencyb .13 (.05) -.16 (.07) 11.18 .001 478.0 
Visuospatial 
Abilityb .14 (.05) .04 (.07) 1.5 .22 472.7 
Episodic 
Memoryb .14 (.04) -.08 (.06) 10.5 .001 459.07 
STMb .09 (.03) -.05 (.05) 5.5 .01 478.0 
Set-Shiftingb .09 (.04) -.23 (.07) 18.3 <.001 488.4 
Inhibition 47.9 (.4) 47.5 (.6) .41 .42 482.3 
Processing 
Speedab .18 (.04) -.05 (.06) 12.67 <.001 481.0 
Abstract 
Reasoning 23.6 (.32) 22.5 (.48) 3.9 .05 472.9 
AFQT 65.3 (1.1) 59.8  (8.4) .004 415.05 
AFQT – Boxes 49.1 (1.6) 43.0 (2.4) 4.9 .03 468.5 
AFQT – Tools 69.0 (1.4) 61.3 (2.1) 11.0 .001 452.7 
AFQT – 
Arithmetic 62.9 (1.5) 56.7 (2.3) 5.9 .02 456.6 
AFQT - 
Vocabulary 84.8 (.95) 82.4 (1.5) 1.9 .17 475.7 
Results are Type III Fixed Effects and are controlled for correlated variance of twin 
data. All cognitive scores were centered with a mean-0, and standard deviation -1.  
Abbreviation: STM= Short-term/working memory; AFQT= Armed Forces 
Qualification Test.  
a Time scores were reverse-coded so that higher scores indicate better performance 
on all measures.  
bMultiple tests were combined to create this variable, and the mean was standardized 
(z-scored). 
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Table 3.5. Change in Cognitive Performance from Baseline to Follow-Up in ED vs. N-ED 
Participants. 
 N-ED  (n=357) 
ED  
(n=134)    
Cognitive Ability M (SE) 
M 
(SE) F p df 
Verbal Fluencyb .04 (.03) .04 (.05) .01 .92 488.4 
Visuospatial 
Abilityb .08 (.04) .1 (.06) .12 .73 486.6 
Episodic Memoryb .05 (.03) .03 (.04) .18 .67 489.0 
STMb .02 (.02) .07 (.04) 1.26 .26 489 
Set-Shiftingb .07 (.04) -.14 (.06) 8.2 .004 483 
Inhibition .12 (.36) .64 (.59) .56 .46 473.1 
Processing Speedab -.04 (.02) -.06 (.04) .24 .63 487.9 
Abstract Reasoning -.4 (.24) .03 (.39) .67 .4 486 
AFQT -.69 -2.8 3.5 .06 489 
AFQT – Boxes -2.07 (1.1) -2.6 (1.8) .07 .8 489 
AFQT – Tools 2.5 (.97) -2.6 (1.6) 7.8 .006 488.2 
AFQT – Arithmetic -2.69 (1.01) -4.21 (1.7) .62 .43 489 
AFQT - 
Vocabulary .74 (.66) -.81 (1.07) 1.54 .22 489 
Results are Type III Fixed Effects and are controlled for correlated variance of twin data. All 
cognitive scores were centered with a mean-0, and standard deviation -1.  
Abbreviation: STM= Short-term/working memory; AFQT= Armed Forces Qualification Test.  
a Time scores were reverse-coded so that higher scores indicate better performance on all 
measures.  
bMultiple tests were combined to create this variable, and the mean was standardized (z-scored). 
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Table 3.6. Percentage of Participants that are “Decliners” in ED vs. N ED Participants. 
 N-ED (n=357) 
ED 
(n=134)   
95% Confidence 
Interval 
  
Cognitive 
Ability %   % 
Odds 
Ratio Lower  Higher 
Chi 
Square 
Value 
p 
Verbal Fluency 3.6 8.2 2.37 1.03 5.42 4.37 .037 
Visuospatial 
Ability 4.5 3.8 .84 .3 2.33 .11 .74 
Episodic 
Memory 4.8 7.5 1.6 .72 3.6 1.37 .24 
STM 5.9 3.0 .49 .17 1.46 1.7 .19 
Inhibition 6.3 3.8 .59 .22 1.6 1.1 .29 
Processing 
Speed 4.2 6.7 1.6 .7 3.85 1.33 .25 
Abstract 
Reasoning 5.1 7.5 1.5 .68 3.39 1.07 .3 
AFQT – Boxes 8.1 11.9 1.53 .80 2.93 1.71 .19 
AFQT – 
Arithmetic 7.0 9.0 1.31 .64 2.68 .53 .47 
AFQT - 
Vocabulary 5.0 11.9 2.55 1.26 5.17 7.19 .007 
Results are Type III Fixed Effects and are controlled for correlated variance of twin 
data.  
Abbreviation: STM= Short-term/working memory; AFQT= Armed Forces 
Qualification Test.  
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GENERAL DISCUSSION 
The history of erectile dysfunction extends as far back as 1700 BC when descriptions of 
impotence were written on scrolls (Parkins, 2001). Since that time, our understanding on the 
causes and consequences of erectile dysfunction has evolved dramatically, with possibly the most 
radical of shifts occurring in the past 30 years. Without a doubt, the discovery by Virag and 
Brindley – that erections can be artificially produced by administration of vasodilatory 
mechanisms – is one of the most influential contributions to the field of sexual dysfunction. From 
this, we learned that erectile dysfunction is not due to witchcraft, oedipal complexes, or a 
degradation of masculinity, but rather is largely due to dysfunction within the vascular system. 
Viagra, the first blockbuster pharmaceutical prescribed for erectile dysfunction, was discovered 
by accident as it was originally being tested as a cardiovascular medication (Berger, 1998). 
Much of the research on the relationships among vascular risk factors, erectile 
dysfunction, and cardiovascular diseases has really burgeoned over the past two decades. From 
this work, erectile dysfunction has been termed “the canary in the coal mine” (Meldrum et al., 
2011), as it is now known to be a powerful predictor of future cardiovascular risk. Just as a 
canary, with its small stature, is more sensitive than humans to carbon monoxide in a mine, the 
penile artery may be more sensitive to vascular dysfunction and atherosclerosis because of its 
relatively small size compared to the rest of the vascular system.  
The first chapter sought to explore the genetic influence on erectile dysfunction. Our 
findings revealed that erectile dysfunction in midlife had a moderate heritability, but that this 
genetic influence appears to decline over time. We also found that prevalence of ED at age 55 
was 48%, which increased to 65% by age 60, which is consistent to rates from other studies with 
similarly aged men (Feldman et al., 1994). 
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The second chapter looked at inflammatory markers and their relationship to ED. It is 
believed that inflammation is part of the causal pathway leading to ED. Gaining a better 
understanding of the inflammatory biomarkers is useful both for diagnosis and management of 
vasculogenic ED, and also informs our understanding of how vascular disease develops. We 
found that while both albumin and globulin were independently related to ED, globulin seemed to 
be the more relevant fraction. However, the albumin/globulin ratio appeared slightly more 
associated with ED than globulin alone. Albumin, globulin, and the albumin/globulin ratio are 
simple, affordable, and routinely collected inflammatory indices, and our findings suggest that 
they are related to severity of erectile difficulties, and may be useful in the diagnosis and 
management of the condition. Future research should be aimed at determining the sensitivity and 
specificity of abnormal proteins levels in diagnosing ED. Since ED is believed to represent 
subclinical vascular disease, gaining a better understanding of how these inflammatory markers 
operate within this disorder may lead to valuable insight about early inflammatory cascades 
within cardiovascular diseases more broadly. 
The third chapter examined the neuropsychological correlates of ED. Because it is known 
that men with vascular disease are at increased risk for cognitive dysfunction, our study sought to 
determine if men with increased risk for vascular disease demonstrated a significantly different 
slope of cognitive decline from their healthy peers. We found that men with ED showed a 
significantly steeper decline in set-shifting (an executive function) and tools/mechanical 
knowledge (strongly associated with testosterone levels). Further, men with ED were more likely 
to demonstrate a statistically significant decline (>1.5 standard deviations from the mean) in 
verbal fluency (another executive function) and vocabulary. Future research is warranted to 
determine if erectile dysfunction is associated with cognitive decline in a group at greater risk for 
cognitive change. It is also unclear to what extent our finding are biased because of the self-report 
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nature of the ED questionnaire, and as such, studies measuring erectile function physiologically 
(e.g. via venous occlusion plethysmography) will be an important part of replicating our results. It 
is known that in many men with ED will remit over time. Future research should determine if 
improvements in erectile functioning are associated with improvements in cognition as well. 
The overarching goal of these three studies is to better characterize ED as a systemic 
condition with biological causes and broad medical and cognitive correlates. Though the medical 
literature is replete with studies on ED as a powerful predictor of morbidity and mortality, the 
gravity of the condition has not been effectively relayed to the public. In a study on barriers to 
treatment in ED, it was found that 43.6% of men who did not seek treatment for ED did so 
because they believed ED was a normal part of aging, 31.4% were waiting for the ED to go away 
on its own, and 26.9% of men were too embarrassed to talk to their physicians about their 
symptoms. These statistics are likely inflated because they were surveying men in primary care 
offices – so men who avoid the healthcare system altogether were not included. Laumann and 
colleagues (1999) found that as low as 10% of men with ED will seek treatment. Although these 
numbers do not speak directly to how many men have discussed erectile difficulties with their 
physician, their rationale for not seeking treatment suggest that a substantial percentage of them 
are either unaware or unconcerned about the medical implications of having ED.  Greater 
emphasis should be placed on the strong relationships ED has with cardiovascular diseases, 
cognitive outcomes, and quality-of-life indices. This would not only aid in decreasing the stigma 
attached to the disorder, but would also bring about opportunities for health care systems to 
intervene and prevent or attenuate further cardiovascular damage.  
In conclusion, by elucidating the complex factors that influence erectile function, we can 
learn more about the prevention and treatment of vascular disease. We have demonstrated the 
significant influence of genetics and inflammation in the development of ED, and have shown 
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that men with ED demonstrate diminished cognitive function and are more prone to decline in 
certain abilities. If the medical community better conveys the intimate relationship between ED 
and cardiovascular health, men may feel more motivated to lead a healthier lifestyle so as to 
avoid developing the condition. Men with existing ED may also be more prone to approach their 
healthcare providers, allowing for greater opportunity for potentially life-saving medical 
intervention. 
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